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 I. SUMMARY 
 
In the more prosperous countries of the world cancer is the cause of death of roughly 
one person in five; the five most common cancers are those of the prostate, breast, 
lung, colon/rectum and the uterine cervix. Cancer is caused by the stepwise 
acquisition of mutations that allow: limitless replicative potential, insensitivity to 
anti-growth signals, evasion of apoptosis, self-sufficiency in growth signals, tissue 
sustained angiogenesis and invasion and metastasis. Two obvious targets for cancer 
drug development are the two cooperating conditions that permit cell expansion; 
deregulated cell proliferation and inhibition of apoptosis 
Stat3, a member of the Signal transducers and activators of transcription (STAT) 
protein family of transcription factors, seems to play a role in cancer progression 
since it is constitutively activated in a wide variety of human malignancies. In 
addition, constitutively active Stat3 is involved in growth promoting and apoptosis 
inhibiting functions in tumor cells. On the other hand cytokine induced activation of 
Stat3 can lead to growth inhibition and apoptosis in some normal and cancerous cells. 
The precise contribution of Stat3 to these different scenarios in cancer cells could not 
be elucidated so far, which makes it difficult to target Stat3 in cancer therapy. The 
aim of this thesis was to investigate the mechanism by which Stat3 controls 
proliferation of tumor cells that are proliferatively inhibited by IL-6 type cytokine 
treatment. Dimerization of IL-6 type cytokine receptors, upon ligand binding, leads 
not only to activation of the JAK-STAT pathway, but also to activation of the 
mitogen activated protein kinase (MAPK) pathway and the phosphatidylinositol 
dependant kinase (PI3K) signaling cascade. To investigate the participation of Stat3 
in IL-6 induced anti-proliferative effects without the influence of the other pathways, 
we have designed an inducible Stat3 construct, in which the entire Stat3 coding 
sequence was fused to the estrogen receptor ligand-binding domain (ER-LBD) that 
can be dimerized by addition of 4-hydroxytamoxifen (4HT). 
Stable expression of this construct in A375 melanoma cells and stimulation with 4HT 
showed that Stat3 activation alone is sufficient for the anti-proliferative effects 
induced by IL-6 type cytokine stimulation. Surprisingly, treatment of cells with a 
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 combination of OSM and 4HT, led to strong and prolonged Stat3 activity, and 
induced cell cycle arrest and apoptosis. These results suggest that Stat3 activation in 
cancer cells, in which IL-6 has anti-proliferative effects, leads to inhibition in tumor 
cell proliferation, whereas strong and prolonged activation of Stat3 induces apoptosis. 
Therefore, for cancer therapy it might be desirable to induce Stat3 activation in these 
specific cases. 
Additionally, we identified the Stat3 target genes that play a role in the observed 
biological effects. Using oligonucleotide microarray analysis and small interfering 
(si) RNA targeting, we showed that the transcription factor C/EBPδ, a Stat3 target, is 
a mediator of Stat3 anti-proliferative effects. Furthermore, using the same techniques, 
we found a novel Stat3 target, the transcription factor TEL (ETV6), which we 
identified as a negative regulator of Stat3 activity and Stat3 induced biological 
functions. The mechanism whereby TEL inhibits Stat3 activity was further 
investigated. Stat3 inhibition by TEL requires histone deacetylase (HDAC) activity 
since addition of Trichostatin A (TSA), a general HDAC inhibitor, blocked TEL 
mediated repression. The pointed domain of TEL was identified as being essential for 
Stat3 inhibition. Interestingly, the DNA binding domain mutant of TEL was still able 
to repress Stat3 activity. Moreover, TEL and Stat3 interact since TEL was detected in 
immunoprecipitates of Stat3.  
Taken together our data show that TEL is a newly identified Stat3 target that 
represses Stat3 transcriptional activity by interacting with Stat3 and recruiting 
HDACs to the transcriptional complex. Therefore, we suggest that TEL might be part 
of a novel negative feedback loop in the Stat3 signaling cascade. 
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 III. Abbreviations 
 
AML   Acute myeloid leukemia  
APRF  Acute-phase response factor  
AR   Androgen receptor  
CAMK2  Ca2+/calmodulin-dependent kinase II  
CDK  Cyclin Dependent Kinase 
C/EBP  CCAAT/enhancer Binding Protein 
CBP  CREB Binding Protein 
CNTF  Ciliary neurotrophic factor  
CRM1  Chromosome Region Maintenance 1 
EGFR   Epidermal Growth Factor Receptor 
EPO  Erytropoietin 
EPOR  Erytropoietin Receptor 
ERK   Extracellular Signal-Regulated Kinase  
ETS  E-Twenty-SIX  
GAS  Gamma interferon activated sequence 
Grb2  Growth Factor Binding Protein 2 
GRIM-19  Gene associated with retinoid-interferon-induced mortality-19  
HAT  Histone acetyltransferase  
HDAC  Histone deacetylase  
4HT  4-hydroxytamoxifen  
IL   Interleukin 
IMP  Importin 
IFN  Interferon ( 
IRF  Interferon Regulatory Factor 
ISG15  Interferon-stimulated gene 15  
JAK  Janus Kinase 
JNK   c-Jun N-Terminal Kinase  
LMB   Leptomycin B  
LPS  Lipopolysaccharide  
MAPK  Mitogen Activated  Protein Kinase 
Mcm  Minichromosome Maintenance 
MEKK1  MAPK/ERK Kinase Kinase 1 
MSK1  Mitogen and stress response kinase-1  
NES  Nuclear Export Signal 
NLS  Nuclear Localisation Signal 
Nmi  N-Myc Interactor 
NPC  Nuclear pore complex  
O- GlcNAc O-linked N-acetylglucosamine  
PDGFR  Platelet Derived Growth Factor Receptor 
PIAS  Protein Inhibitor of Activated STAT 
PI3K  Phosphatidylinositol Dependant Kinase 
PKCδ   Protein Kinase C δ  
PP2A   Protein phosphatase 2A  
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 PRMT-1  Protein Arginine Methyltransferase-1  
PTPase  Protein tyrosine phosphatase  
PTPεC  PTPepsilonC  
RTK  Receptor tyrosine kinase 
SCID   Severe combined immunodeficiency  
SCID  Severe combined immune deficiency  
SH2  Src Homology Domain 2 
SHP2  Src homology domain 2 protein tyrosine phosphatase 
SOCS  Suppressor of Cytokine Signaling 
STAT  Signal Transducer and Activator of Transcription 
Stat3DN  Dominant negative Stat3  
SUMO  Small ubiquitin-related modifier  
TAD   Transactivation domain 
TC-PTP   T cell protein tyrosine phosphatase  
Tip 60  Tat-interactive protein, 60kDa  
TPPII  Tripeptidyl peptidase II  
TSA   Trichostatin A  
Ub   Ubiquitin  
Y   Tyrosine 
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 IV. Introduction 
STATs in signal transduction 
 
Signal transducers and activators of transcription proteins (STATs) are a family of latent 
cytoplasmic transcription factors that are activated in response to extracellular stimuli. 
They have first been discovered in interferon (IFN) regulated gene transcription, 
specifically Stat 1 and Stat2 (Schindler et al., 1992b). Today seven STAT members have 
been identified in mammalian cells: Stat1, Stat2, Stat3, Stat4, Stat5a, Stat5b and Stat6 
ranging in size from 750-850 amino acids resulting in proteins of 90 –115 kDa that are 
abundantly present in many cell types. As a result of series of duplication processes, the 
STAT family is genetically localized to three chromosomal regions, (Table 1) (Copeland 
et al., 1995). 
 
 
  Murine       Human 
Stat1     1   2q32.3  
Stat2   10   12q13.3 
Stat3   11   17q21.2 
Stat4     1   2q32.2 
Stat5a   11   17q21.2 
Stat5b   11   17q21.2 
Stat6   10   12q13.3 
Family member       Chromosomal localization  
 
 
 
 
 
 
 
 
 
Tabel 1: STAT chromosomal localization. Adapted from (Benekli et al., 2003) 
 
 
STAT Structure 
 
The analysis of crystallographic studies: of Stat1 and Stat3 core amino acids (residues 
~130-712; lacking an N-terminal and C-terminal domain) bound to DNA, of the NH2 
terminus of Stat4 (Fig.1), as well as mutagenesis studies revealed several regulatory 
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 common domains of the STAT proteins (Becker et al., 1998; Chen et al., 1998; Darnell, 
1997; Vinkemeier et al., 1998). 
 
Fig. 1: Three-dimensional structure of STAT 1 proteins. The core structure (amino 
acids 130–712) shows binding of a STAT1 dimer to DNA and the location of binding 
sites of various proteins in various domains. The N-terminal structure, the placement 
of which in the intact structure is undefined, also interacts with various partners, as 
does the C-terminal transactivation domain, the structure of which is unknown. 
Adapted from (Levy and Darnell, 2002). 
 
 
The STAT structure is illustrated in (Fig. 2). The N-terminal region of STAT is important 
for protein-protein interactions and for dimer-dimer interactions to form tetrameric STAT 
molecules. Many natural STAT binding sites are in close proximity of each other (~ 20 
base pairs apart) and are occupied by tetramers (dimer–dimer pairs) (Darnell, 1997). 
Deletion of the amino terminus leads to STAT binding to single sites, tetramers are not 
formed. In addition, it has been shown that tetramer formation is necessary for a strong 
STAT–DNA interaction at adjacent sites and is important for maximal transcriptional 
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 stimulation (John et al., 1999; Vinkemeier et al., 1996; Xu et al., 1996; Zhang and 
Darnell, 2001). Contiguous to the oligomerization domain is a four-stranded helical  
coiled coil domain from residue ~130-320, which provides an extensive surface to 
interact with other proteins, for example CBP/p300 (Zhang et al., 1996). Additionally it 
has been shown that the N-terminus is involved in receptor recognition, phosphorylation, 
nuclear translocation, and dephosphorylation (Murphy et al., 2000; Strehlow and 
Schindler, 1998). 
The DNA binding domain, between residues 320 and 490, contains several β-sheets and 
determines DNA sequence specificity of individual STATs.  Following the DNA binding 
domain is a linker domain (residues 490 to 580) with a highly conserved structure but to 
date unknown function. Mutations within this domain inhibit Stat1 driven transcription 
after IFN-γ stimulation due to rapid on-off-rates of Stat1 on the DNA, which results in 
reduced binding times (Yang et al., 2002a; Yang et al., 1999).  
The Src- homology 2 (SH2) domain that extends between residues 580 and 680 is a well 
known common structural motif, which mediates dimerization via SH2-phosphotyrosyl 
peptide interactions (Shuai et al., 1994). The critical STAT tyrosine residue (700) that is 
phosphorylated upon activation and required for dimerization via SH2 is near the SH2 
domain. A Transactivation domain (TAD) at the COOH-terminal end of the molecule, 38 
to 200 residues in length, depending on the various STAT proteins, is involved in 
interaction with transcription complexes. The C-terminus contains one more interesting 
feature, in the case of Stat1, Stat3, Stat4 and Stat5, a serine phosphorylation site, which 
has been shown to contribute to transcriptional activation and seems to be important for 
protein-protein interactions (Decker and Kovarik, 2000).  
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Fig. 2: Domain structures of STAT proteins. Adapted from (Bowman et al., 2000) 
 
STAT isoforms 
Naturally occurring splice variants of STATs lacking regions of the C-terminal 
transactivation domain, including the serine residue, have a competitive dominant-
negative (DN) effect on gene induction, mediated by the STAT pathway, counteracting 
the signaling of the full length STAT. 
The truncated isoforms still get tyrosine phosphorylated, dimerize and bind DNA where 
they exert their dominant negative effect by blocking the DNA-binding sites in STAT 
responsive gene promoter elements. So far splice variants of Stat1, Stat3 and Stat5 have 
been identified, named Stat1β, Stat3β, and Stat5β, that can be generated by two distinct 
mechanisms: alternative mRNA splicing and proteolytic processing (Caldenhoven et al., 
1996; Moriggl et al., 1996; Sasse et al., 1997; Schaefer et al., 1997; Schindler et al., 
1992a; Wang et al., 1996). Splicing joins the coding sequences (exons) by removing the 
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 intervening noncoding sequences (introns) from primary transcripts. Thus, alternative 
splicing can lead to a vast repertoire of functional diversity by producing multiple RNAs 
and proteins from a single gene. Compared to wild-type Stat3, Stat3β has seven new 
amino acids and lacks an internal domain of 50 base pairs from the C terminal of Stat3 
(Fig 3). This splice product is a naturally occurring isoform of Stat3 and encodes a 80-
kDa protein which also lacks the Ser 727 phosphorylation site (Caldenhoven et al., 1996). 
In the case of proteolytic processing, Stat5 has been reported to be truncated at the 
transcriptional activation domain (Azam et al., 1997; Lee et al., 1999). STATβ splice 
variants function as negative regulators of transcription and are therefore widely used to 
study the role of STAT proteins.  
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Fig. 3: Domain structures of Stat3 isoforms. Adapted from (Bowman et al., 2000) 
 
 
Mechanisms of STAT activation and regulation 
 
STATs are activated by over 40 different polypeptides binding cytokine receptors, G-
protein-coupled receptors, receptor tyrosine kinases like epidermal growth factor receptor 
and platelet derived growth factor receptor (EGFR and PDGFR) and by numerous non-
receptor tyrosine kinases (e.g. Src and Abl) (Fig. 4).  
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Fig. 4: Activators of STAT proteins. Adapted from (Bromberg, 2001) 
 
For cytokine receptors it has been shown that receptor associated JAKs (Janus Kinases) 
phosphorylate STATs (Greenlund et al., 1995; Madamanchi et al., 2001; Marrero et al., 
1995; Park et al., 2000b). In the case of growth factors such as the EGF and PDGF, that 
bind to receptor tyrosine kinases (RTKs), STAT activation can take place either directly 
(for example Stat1 activation by PDGF) or via other associated non-receptor tyrosine 
kinases (e.g. JAK and Src) (Leaman et al., 1996; Olayioye et al., 1999; Vignais et al., 
1996; Wang et al., 2000b) (Fig. 5). In addition, non-receptor tyrosine kinases such as 
activated Src and ABL can directly phosphorylate STAT proteins in the absence of ligand 
induced receptor activation (Fig. 5) (Cao et al., 1996; Danial and Rothman, 2000; Yu et 
al., 1995). Phosphorylation of STATs results in homodimerization or heterodimerization 
through reciprocal interaction between SH2 domains and phosphotyrosines. Stat1, Stat3, 
Stat4, Stat5a and Stat5b form homodimers. Stat1 and Stat2 and Stat1 and Stat3 can also 
form heterodimers. As a result, STAT dimers translocate to the nucleus where they bind 
to specific STAT DNA-binding elements, originally termed the GAS (gamma interferon 
activated sequence) element (TTN5-6AA), in the promoter of target genes and activate 
transcription (Bromberg et al., 1999; Levy and Darnell, 2002; Seidel et al., 1995).  
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Fig. 5: Overview of STAT signaling. STATpY, tyrosine-phosphorylated STAT; pS, 
serine-phosporylated. Adapted from (Levy and Darnell, 2002)  
 
 
Perhaps the best-studied pathway for STAT activation is through the JAKs otherwise 
knows as the JAK-STAT pathway (Fig. 6). Binding of IL-6-type cytokines to their 
specific receptors leads to hetero-oligomerization with the common signal transducer 
gp130, resulting in phosphorylation and activation of the receptor associated Janus 
kinases (Jaks). Subsequently five tyrosines in the cytoplasmic tail of gp130 get 
phosphorylated. The phosphorylated tyrosines serve then as docking sites for two major 
signal-transducing molecules; SHP2 (Src homology domain 2 protein tyrosine 
phosphatase) binds at Tyr759 and interacts with adaptor molecules such Gab 1/2, p85 and 
Grb2 mediating the activation of intracellular signaling pathways such as the mitogen-
activated protein kinase  (MAPK) or the phosphatidylinositol-3 phosphate (PI3K) 
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 pathways (Qu, 2002). Binding of Stat3 at Tyr767, 814, 905, and 915 of gp130 (Heinrich 
et al., 1998; Schmitz et al., 2000a) is followed by JAK-induced phosphorylation of 
 STATs.  
 
 
 
Fig. 6: JAK–STAT pathway. Adapted from (Levy and Darnell, 2002) 
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 JAK family kinases 
There are four mammalian members of the JAK family of tyrosine kinases: JAK1, JAK2, 
JAK3, and Tyk2 known. They range in size from 120 to 130 kDa and expression studies 
indicate that JAK1, JAK2 and TYK2 are ubiquitously expressed. JAK3 is expressed 
predominantly in cells of hematopoietic origin (Leonard and O'Shea, 1998). The 
chromosomal location in humans has been mapped to 1p13.3 for JAK1, 10q23-q24 for 
JAK2, 19p13.2 for TYK2 and 19p13.1 for JAK3 (Firmbach-Kraft et al., 1990; Ihle et al., 
1995; Kumar et al., 1996; Pritchard et al., 1992; Riedy et al., 1996). JAKs consist of 
seven conserved JAK homology (JH) domains (Fig. 7). The most interesting feature of 
the JAK proteins is the presence of two domains in the C-terminal portion of these 
molecules including a distinctive pseudokinase domain (JH2) and a tyrosine kinase 
domain (JH1), although only the JH1 domain appears to be functional. The JH2 domain, 
which shows considerable homology to the tyrosine kinase domain, lacks certain critical 
amino acids required for a functional kinase. However, an important regulatory function 
in regards to kinase activity was attributed to the JH2 domain (Luo et al., 1997; Saharinen 
et al., 2000). Additionally Fujitani et al (1997) described the JH2 domain as an 
interaction site with Stat5 providing a different way of activation of Stat5 (Fujitani et al., 
1997). Interestingly, SH2 or SH3 domains are missing in JAKs, it has been shown that 
the JH3 domain shares homology with SH2 domains, however, binding of 
phosphotyrosine to this domain has not been reported. The amino-terminal JAK 
homology domains, JH7–JH3, follow a non-conserved amino terminus of ~ 30-50 amino 
acids, constituting a FERM (four-point-one, ezrin, radixin, moesin) domain which 
mediates association with receptors.  
  Receptor binding region Pseudo-kinase  
      domain 
    Kinase  
   domain 
N 
      JH7         JH6      JH5      JH4        JH3              JH2                      JH1 
Y
Y  Y
C 
Fig. 7: Domain structure of JAK. JH: JAK homology 
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 JAK kinases are essential for the action of type I and type II interferons (IFN), while they 
are also activated by many other cytokines (Table 2) (Imada and Leonard, 2000). 
Cytokines JAK-kinase 
IFNs 
 
IFNα/β, IL-10 
IFNγ 
 
 
JAK1, TYK2 
JAK1, JAK2 
Cytokines whose receptors share γc 
 
IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 
 
 
JAK1, JAK3, JAK2, TYK2 
Cytokines whose receptors share βc 
 
IL-3, Il-5, GM-CSF 
 
 
JAK2 
Cytokines whose receptors share gp130 
 
IL-6, IL-11, OSM, CNTF, LIF, CT-1 
IL-12 
 
 
JAK1, JAK2, TYK2 
JAK2, TYK2 
Cytokines whose receptors are homodimers 
 
Growth hormone, Prolactin, EPO, TPO 
 
 
JAK2 
 
Table 2: Activation of JAKs by cytokines. Adapted from (Imada and Leonard, 2000) 
Although specific JAKs are activated through each cytokine receptor and may partially 
contribute to specificity, the JAK kinases by themselves are not an absolute determinant 
of the specificity in cytokine signaling, since many different cytokines activate the same 
JAKs. Nevertheless, JAK gene targeting studies have identified characteristic signaling 
defects (Table 3). These studies indicate that JAK1–/– mice exhibit a perinatal lethal 
phenotype but lack other abnormalities. They are small at birth and fail to nurse, 
lymphopoiesis but not myelopoiesis is severely impaired. They fail to respond to 
cytokines that bind three distinct families of cytokine receptors, including IFNs (type II 
cytokines), γc-dependent cytokines, and gp130 dependent cytokines (Rodig et al., 1998). 
The JAK2 knockout mice exhibit embryonic lethality (i.e., day 12.5), due to the absence 
of definitive erythropoiesis; additional immunological impairments caused by impaired 
cytokine signaling are observed (Neubauer et al., 1998; Parganas et al., 1998). Tyk2 
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 knockout mice exhibit increased pathogen susceptibility caused by impaired responses to 
interferon and IL-12 (Karaghiosoff et al., 2000; Shimoda et al., 2000). The most relevant 
knockout for human disease is that of JAK3, whose product exhibits a relatively exclusive 
association with the γcommon receptor chain. Mutations in the common cytokine receptor 
chain, which is shared by the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, cause 
severe combined immunodeficiency (SCID) in humans (Leonard, 1996; Noguchi et al., 
1993). Likewise, JAK3–/– mice demonstrate profound reduction in thymocytes, B cells 
and T cells similar to (SCID); due to failure of cytokine signaling from γc-containing 
receptors (Nosaka et al., 1995; Park et al., 1995; Thomis et al., 1995). Indeed mutations in 
JAK3 have been found to lead to severe combined immunodeficiency disease (SCID) in 
some patients (Macchi et al., 1995; Russell et al., 1995). 
 Aberrant JAK kinase activity has also been implicated in various human malignancies, 
such as leukemia (Verma et al., 2003). For example, chromosomal translocation of the 
short arm of chromosome 9, containing the kinase domain of JAK2, to the short arm of 
chromosome 12, containing the pointed domain of TEL, results in a fusion protein TEL-
JAK2 with an overactive kinase. TEL-JAK2 fusion proteins have been found in lymphoid 
and myeloid leukemia (Lacronique et al., 1997). Ectopical overexpression of TEL-JAK2 
in hematopoietic cell lines leads to constitutive activation of Stat1, Stat3 and Stat5 and 
induces growth factor independent proliferation (Schwaller et al., 1998).  
 
Viable and fertile, impaired IFN and IL-12 response, increased pathogen 
susceptibility 
TYK2 
Viable and fertile, SCID JAK3 
Embryonic lethality, due to failure in erythropoiesis, impaired cytokine 
signaling 
JAK2 
Viable but perinatal lethality due to neurological defects, SCID JAK1 
Phenotype of null mice Gene 
Table 3: Phenotype of JAK knockout mice. Adapted from (O'Shea et al., 2002) 
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 Posttranslational Modifications of STAT proteins 
In addition to tyrosine phosphorylation, STATs are also subject to other posttranslational 
modifications such as serine phosphorylation, methylation, acetylation, ISGylation, 
ubiquitylation, sumoylation and glycosylation (Table 4).  
No clear function sumoylation 
Degradation of STATs ubiquitylation 
Activation of Stat5 glycosylation 
Increased DNA binding of Stat1 arginine methylation 
Positive feedback loop of Stat1 ISGylation 
Activation of Stat6 acetylation 
Enhances activation of STATs serine phosphorylation 
Activation of STATs 
Post-translational modifications of STATs Biological function 
tyrosine phosphorylation 
 
Table 4: Post-translational modifications of STATs 
Serine phosphorylation has been described for Stat1 and Stat3 at serine 727, Stat4 at 
serine 721, Stat5a at serine 725, Stat5b at serine 730 and for Stat6 at unknown serines in 
the region between residues 719-789 (Beuvink et al., 2000; Pesu et al., 2000; Visconti et 
al., 2000; Wen et al., 1995; Wick and Berton, 2000; Yamashita et al., 1998). Different 
kinases have been reported to participate in serine phosphorylation of STATs contingent 
on the cell type and the cytokine/growth factor studied (Table 5). 
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Kinase Reference: 
Ca2+/calmodulin-dependent kinase II 
(CAMK2) 
(Nair et al., 2002) 
c-Jun N-terminal kinase (JNK) (Decker and Kovarik, 2000) 
extracellular signal-regulated kinase (ERK) (Chung et al., 1997b) 
MAPK/ERK kinase kinase 1 (MEKK1) (Lim and Cao, 2001) 
mitogen and stress response kinase-1 
(MSK1) 
(Wierenga et al., 2003) 
p38 MAPK (Uddin et al., 2002; Xu et al., 2003) 
Pak1 (Wang et al., 2003) 
PI3K (Fung et al., 2003) 
protein kinase C δ (PKCδ) (Jain et al., 1999; Schuringa et al., 2001; 
Schuringa et al., 2000; Uddin et al., 2002) 
 
Table 5: Potential serine/threonine kinases of STATs.  
Serine phosphorylation enhances transcriptional activity of Stat1, Stat3 and Stat4 (Decker 
and Kovarik, 2000; Visconti et al., 2000; Wen et al., 1995). More recent data shows on 
the other hand that serine phosphorylation enhances the ability of Stat1 to drive 
expression of some, but not all target genes (Kovarik et al., 2001). There seems to be no 
consequence of serine phosphorylation on nuclear translocation of Stat1/Stat3 and 
Stat5a/Stat5b (Decker and Kovarik, 2000; Yamashita et al., 1998). However, serine 
phosphorylation might be important for the duration of stimulation, since a Stat5a serine 
725 mutant displayed sustained DNA binding activity compared with DNA-binding of 
wild type Stat5a (Beuvink et al., 2000).  
Methylation of arginine 31 in the N-terminal domain, which is conserved in STATs, by 
protein arginine methyltransferase-1 (PRMT-1), has been reported in the case of Stat1. 
This methylation is independent of tyrosine or serine phosphorylation and does not 
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 require cytokine stimulation. Interestingly, methylation leads to a weaker interaction of 
Stat1 with protein inhibitor of activated STATs (PIAS) 1, resulting in increased DNA-
binding of Stat1 (Mowen et al., 2001). PRMT has been associated with other elements of 
the JAK/STAT pathway, as PRMT-1 interacts with the IFNα/β receptor 1 and PRMT-5 
interacts with JAKs (Abramovich et al., 1997; Pollack et al., 1999). 
 Acetylation of Stat6 by histone acetyltransferase CREB-binding protein (CBP)/p300 is 
required for transcriptional activation of the 15-lipoxygenase-1 (15-LOX-1) by IL-4 
(McDonald and Reich, 1999; Shankaranarayanan et al., 2001).  
Recent studies have demonstrated a positive regulatory role for ISGylation in the 
JAK/STAT signaling pathway. ISGylation of JAK1 and Stat1 is achieved by interferon-
stimulated gene 15 (ISG15) a ubiquitin-like protein that conjugates to numerous proteins 
in cells treated with IFNα or lipopolysaccharide (LPS). (Malakhov et al., 2003; 
Malakhova et al., 2003). 
 Interestingly, new results show the essential function of O-linked N-acetylglucosamine 
(O- GlcNAc) on threonine 92, as a posttranslational modification, which seems to be 
important for the transcriptional activity of Stat5. O-linked glycosylation has only been 
seen on nuclear Stat5 following cytokine stimulation, however, glycosylation seemed not 
to be a requirement for nuclear translocation of Stat5. Mutational analysis demonstrated 
that Stat5, which cannot be glycosylated was not able to activate a reporter gene 
construct. The authors concluded this failure to the impaired interaction of un-
glycosylated Stat5 with CBP. Since glycosylation was also observed on other STATs, it 
seems likely that this posttranslational modification might be essential for interaction 
with co-activators following cytokine stimulation (Gewinner et al., 2003). Ubiquitylation 
and sumoylation will be described in the section “Negative Regulators of STATs”. 
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 Nuclear Import and Export of STAT proteins  
STAT proteins translocate to the nucleus upon Tyr phosphorylation and dimerization and 
translocate back into the cytoplasm after dephosphorylation in the nucleus. This 
processes are widely studied by various groups and dependent on active transport through 
the nuclear pore complex (NPCs), since STAT dimers are too large (> 50kD) for passive 
diffusion through the NPC. Expression of a nuclear localization signal (NLS) is essential 
for active transport of molecules through the nuclear pore. NLS signals are usually either 
single stretches or double stretches of residues, which have a high content of basic 
arginine and lysine amino acids, spaced by around 10 nonconserved residues (Dingwall 
and Laskey, 1991). Members of the importin α (impα) family, which includes 6 family 
members and each member features 8 to 10 Armadillo (Arm) repeats, bind to NLS 
signals in proteins that are targeted for nuclear transport. Importin β then binds to impα 
and carries impα and its cargo protein, via binding to nucleoporins in the NPC, through 
the NPC into the nucleus where it associates with Ran-GTP, which leads to the release of 
impα and its load. Nuclear export, similar to the nuclear import, requires also the 
presence of a special signal, a hydrophobic nuclear export signal (NES), as well as 
soluble carriers named exportins. There are specific exportins such as CAS, which is 
important for export of impαs, while there are also more general exportins like CRM1 
(chromosome region maintenance 1). CRM1 identifies NESs, which consists of a short 
sequence with hydrophobic amino acids rich in leucine, and binds the NES carrying 
cargo together with Ran-GTP to form a stable ternary complex. The complex travels 
through the NPC and dissociates in the cytoplasm after the hydrolysis of Ran-GTP. 
Leptomycin B (LMB), an antibiotic, binds irreversibly to CRM1, blocks its ability to bind 
to the NES and therefore inhibits its activity (Fig.8) (McBride and Reich, 2003) 
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Fig. 8: Depiction of nuclear trafficking. Adapted from (McBride and Reich, 2003).  
Recent studies indicate a NLS signal, including leucine 407 and lysines 410 and 413 
within the DNA binding domain of Stat1 and interaction of impα5 with tyrosine-
phosphorylated Stat1 (Fagerlund et al., 2002; McBride et al., 2002; Melen et al., 2001). 
Stat1 nuclear export is achieved via a NES, residues 399-410, within the DNA binding 
domain, and CRM1 binding to this area (McBride et al., 2000). A second NES domain, a 
leucine-rich helical segment, has been described in the N terminus of Stat1 (Begitt et al., 
2000). However, CRM 1 binding to this region has not been reported yet, which leads to 
the assumption that this region participates in a different manner in nuclear export. 
Interestingly the NES of Stat1 seems to be hidden, when Stat1 is bound to the DNA and it 
is therefore essential to dislodge Stat1 from the DNA for tyrosine dephosphorylation, 
which leads to the accessibility of the NES by CRM1 and the nuclear export of Stat1 
(Meyer et al., 2003). Potential protein tyrosine phosphatases will be described later under 
“Protein tyrosine phosphatases (PTPases)”. 
Bild et all. showed that Stat3 is associated with endocytotic vesicles during the transport 
through the cytosol arguing that receptor-mediated endocytosis is a requirement for Stat3 
shuttling from the plasma membrane to the perinuclear region (Bild et al., 2002). 
Nevertheless, several points speak against this observation since constructs such as 
Stat3ER and Stat3-C have been shown to translocate to the nucleus without receptor 
activation (Bromberg et al., 1999; Milocco et al., 1999) in addition, two NLS have been 
reported recently for Stat3. One in the in the alpha-helix 2 region of the coiled-coil 
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 domain, where arginines 214-215 have been shown to include a novel Stat3 NLS, which 
can be stimulated by epidermal growth factor as well as by interleukin-6. Of great 
surprise is that truncation mutants containing only the N-terminal and coiled-coil domain 
of Stat3 are localized to the nucleus without ligand stimulation (Ma et al., 2003). In 
addition to the area in the coiled-coil domain a NLS has been identified in the DNA 
binding domain, arginines 414-417, which correspond to lysines 410-413 of Stat1, a 
known Stat1 NLS (Fagerlund et al., 2002; Ma et al., 2003). On the other hand, leucine 
411 of Stat3, corresponding to leucine 407 of Stat1, a necessary residue for Stat1 nuclear 
transport, is not essential for Stat3 nuclear import (Ma et al., 2003).  
Nuclear export of Stat3 is achieved via three nuclear export signal (NES) elements. Two 
of these elements, 306-318 and 404-414, corresponde to those recently identified in Stat1 
399-410, and a third, Stat3 524-535, is novel (Bhattacharya and Schindler, 2003; 
McBride et al., 2000). It is also possible to block nuclear export of Stat3 by leptomycin B 
as it is the case for Stat1 (Bhattacharya and Schindler, 2003; Nakayama et al., 2002). In 
contrast to Stat1 LMB treatment not only blocks the export of Stat3 from the nucleus 
back to the cytoplasm after activation, but also promotes nuclear accumulation of Stat3 in 
resting cells, leading to the assumption that there might be non tyrosine phosphorylated 
monomer Stat3 in the nucleus.  
Similar to Stat3 Stat5b demonstrates monomer shuttling between the nucleus and the 
cytoplasm, since LMB treatment in the absence of cytokine, led to the accumulation of 
Stat5B in the nucleus (Zeng et al., 2002). The authors further support this concept with 
the observation that a mutated Stat5b, which has the Tyr 699 important for 
phosphorylation and dimerization mutated, also accumulates in the nucleus after LMB 
treatment (Zeng et al., 2002). Thus Stat3 and Stat5b appear to have constitutive NLS and 
NES function that promotes shuttling of monomeric STATs. This might happen in a 
different way than the shuttling of tyrosine phosphorylated dimerized STATs. Growth 
hormone-induced nuclear import of Stat5b seems to rely on a NLS in the DNA-binding 
domain, 466-469, (Herrington et al., 1999). Furthermore, deletion of the region up to 
residue 104 inhibit translocation of factor stimulated Stat5b, whereas region between 
residues 138 and 165 is essential for cytokine independent import of Stat5b. A putative 
 26
 NES is located in the region between residues 578-723 of Stat5b, this export is LMB 
sensitive (Zeng et al., 2002). Given that Stat2 is not able to form homodimers and the fact 
that Stat2 is constitutively associated with interferon regulatory factor-9 (IRF-9), it was 
shown that Stat2 localizes to the nucleus as part of a Stat1-Stat2-IRF-9 complex (Lau et 
al., 2000; Martinez-Moczygemba et al., 1997; McBride et al., 2002). So far there are no 
reports about NLS or NES in Stat4 and Stat6.  Nevertheless, it is of interest that STAT 
molecules that dimerize without tyrosine phosphorylation are able to translocate to the 
nucleus, as it is shown for Stat1, Stat3, Stat5 and Stat6 (Bromberg et al., 1999; Milocco et 
al., 1999). This suggests that dimerization alone is sufficient to unmask a latent STAT 
nuclear localization sequence and induce nuclear translocation, sequence-specific DNA 
binding, and transcriptional activity. 
Negative Regulators of STATs  
The transient nature of STAT activation suggests that nature has also invented 
sophisticated mechanisms to turn off the signaling pathway. In fact, recent studies show 
that STAT signaling is negatively regulated at different points in the signaling cascade 
including by dephosphorylation and endocytosis of the receptors, dephosphorylation of 
the JAKs and STATs (Fig. 9a, 9c), proteolytic degradation of: the receptors, the STAT 
proteins or the JAKs and via two different protein families; the suppressors of cytokine 
signaling family (SOCS) and proteins that inhibit activated STAT proteins family (PIAS) 
(Fig. 9b, 9d). In addition, inhibition is achieved by splice variants (see section “STAT 
isoforms”) (Fig. 9e). The different mechanisms of inhibition will be explained in the 
following sections.  
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Fig. 9: Negative regulators of STAT molecules (Levy and Darnell, 2002). 
Receptor mediated endocytosis 
The function of the plasma membrane is to separate the cytoplasm of a cell from the 
extracellular environment. The coordination of the exit or entry of small and large 
molecules via regulating mechanisms plays an important role. Small molecules for 
example amino acids, sugars and ions, can enter the cells via the aid of integral 
membrane protein pumps or channels. Endocytosis is a term for a process where 
macromolecules cross the plasma membrane in endocytic vesicles. A small portion of the 
plasma membrane, that encloses the macromolecule and then invaginates and pinches-off 
forms the vesicles. Two main types of endocytosis occur, phagocytosis (“cellular 
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 eating”), which involves the ingestion of large particles, such as microorganisms or dead 
cells and pinocytosis (“cellular drinking”), the uptake of fluid and solutes. Phagocytosis 
is typically restricted to specialized mammalian cells, whereas pinocytosis occurs in all 
cells by at least four basic mechanisms: macropinocytosis, clathrin-mediated endocytosis 
(CME), caveolae-mediated endocytosis, and clathrin- and caveolae-independent 
endocytosis (Fig. 10) (Conner and Schmid, 2003). 
 
Fig. 10: Multiple portals of entry into the mammalian cell. Adapted from (Conner 
and Schmid, 2003) 
An important function of endocytosis in cell signaling is to downregulate signal 
responses by internalizing receptors either constitutively or upon ligand binding. This 
provides an excellent mechanism to inhibit many signaling pathways by constitutively 
internalizing a pool of receptors from the plasma membrane and via switching off 
signaling after ligand binding. Signal transduction by the receptor would otherwise occur 
indefinitely once it had been initiated. Recruitment of clathrin to internalization signals 
within cytosolic tails of receptors at the plasma membrane leads to invagination of the 
receptors. Evidence of receptor mediated endocytosis as a negative regulation of STAT 
signaling originate from studies that indicated that the IL-6R is downregulated by its 
ligand (Zohlnhofer et al., 1992). Recent data demonstrate that the common signal 
transducer gp130 carries a di-leucine internalization motif within the intracellular domain 
(Dittrich et al., 1994). In addition, mutation of serine 139 to an alanine of gp130 reduces 
the internalization rate by 50 % suggesting that serine phosphorylation upon IL-6 
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 stimulation leads to a conformation change and exposure of the internalization signal to 
the endocytotic machinery (Dittrich et al., 1996). 
Targeted Degradation 
Ubiquitylation, the conjugation of proteins with a protein called ubiquitin (Ub), is 
essential for the degradation of proteins whose levels have to be regulated either 
constitutively, or in response to extracellular stimuli and changes in the cellular 
environment. Ubiquitylation is a multistep process involving at least three types of 
enzymes (Fig. 11). 
 
Fig. 11: The ubiquitin pathway. Adapted from (Tisdale, 2002). 
Free ubiquitin is activated in an ATP-dependent manner, by the activity of an ubiquitin-
activation enzyme (E1), leading to the formation of a thiol-ester linkage between E1 and 
the carboxyl terminus of ubiquitin (glycine 76). Subsequently, the ubiquitin group is 
transferred to one of many distinct ubiquitin-conjugating enzymes (E2). Finally, a 
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 ubiquitin protein ligase (E3) catalyses the transfer of Ub from the E2 enzyme to the target 
protein. Specificity arises from the different enzymes that are involved in mediating 
ubiquitylation as well as the types of the ubiquitin complex that are formed, 
multiubiquitylation serves mainly to label the substrate for degradation whereas 
monoubiquitylation regulates numerous processes, for instance endocytosis, DNA repair 
and transcriptional regulation (Aguilar and Wendland, 2003). Degradation of 
ubiquitylated substrates is performed by the 26S proteasome, which is composed of the 
two terminal 19S regulatory subcomplexes bound to the proteolytic 20S core. Substrates 
destined for degradation are labeled with polyubiquitin (Ubn), which is recognized by the 
19S complex. Short oligopeptides are released from the 26S proteasome after degradation 
and are then further degraded into tripeptides by the protease tripeptidyl peptidase II 
(TPPII). Ubiquitin-proteosomal degradation is important for downregulation of the 
JAK/STAT signaling pathways. It was shown with the use of proteasome inhibitors that 
JAK1, JAK2 and JAK3 are targets for degradation (Ungureanu et al., 2002; Yu and 
Burakoff, 1997) as well as tyrosine phosphorylated Stat1 Stat4, Stat5 and Stat6 with only 
marginal effects on Stat2 and Stat3 (Kim and Maniatis, 1996; Ulane et al., 2003; Wang et 
al., 2000a). In addition, a C-terminal domain in Stat5 promotes degradation, since 
deletion of this domain resulted in a protein that was more stable compared to the 
wildtype protein (Wang et al., 2000a).  
Protein tyrosine phosphatases (PTPases) 
Dephosphorylation is an important way of inhibition of the STAT signaling pathway and 
can occur in the cell cytoplasm, where the receptor, the JAKs and the STATs are targets, 
as well as in the nucleus where dephosphorylation of the STATs takes place. Today 
several PTPs have been identified that negatively regulate the JAK/STAT pathway 
(Table 6).  
The first cytoplasmic tyrosine phosphatases found to be involved in inhibiting JAK 
activity were the closely related SH2 containing phosphatases (SHP), SHP1 and SHP2 
(David et al., 1995; Jiao et al., 1996; Klingmuller et al., 1995; Symes et al., 1997; Wu et 
al., 2002; You et al., 1999). SHP1 is mainly expressed in hematopoietic tissues, whereas 
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 SHP2 is ubiquitously expressed. All tyrosine-phosphorylated signaling molecules such as 
receptors, JAKs or STATs have to be considered as possible targets for SHP2. However, 
direct interaction has only been shown with SHP1, JAK1 and JAK2 (Jiao et al., 1996) 
and for SHP2 with JAK1 and Stat5 (Chen et al., 2003; Chughtai et al., 2002; Yin et al., 
1997). More phosphatases may play a role in cytoplasmic deactivation of the STATs but 
they have not been found yet. The transmembrane PTPase CD45 is highly expressed in 
all haematopoietic lineages and binds and dephosphorylates JAKs (Irie-Sasaki et al., 
2001). Other PTPases, expressed in haematopoietic cells, are PTPepsilonC (PTPεC) and 
the T cell protein tyrosine phosphatase (TC-PTP). The inhibitory effect of PTPεC is 
selective for IL-6- and IL-10-induced JAK-STAT signaling (Tanuma et al., 2000; 
Tanuma et al., 2001). JAK1 and JAK3 are physiological substrates of TC-PTP and 
phosphorylation of Stat5 following interleukin (IL)-2 stimulation is abrogated in T cells 
that overexpress TC-PTP (Ibarra-Sanchez et al., 2000; Simoncic et al., 2002). A cytosolic 
phosphatase PTP1B has been shown to dephosphorylate JAK2 and TYK2, but not JAK1, 
in response to interferon stimulation. Additionally, PTP1B dephosphorylates prolactin 
(PRL) activated Stat5a and Stat5b, thereby negatively regulating the PRL-mediated 
signaling pathway. (Aoki and Matsuda, 2000; Myers et al., 2001). The PRL-mediated 
signaling pathway can also be inhibited by PTP-PEST, since it was shown that PRL 
activation of JAK2 was dramatically reduced in HC11 cells pretreated with EGF, and that 
PTP-PEST, which is constitutively associated with JAK2, can be upregulated in response 
to EGF treatment (Horsch et al., 2001). Interestingly, the serine/threonine protein 
phosphatase 2A (PP2A) is associated with Jak2 and Stat5 in an IL-3-dependent manner. 
PP2A is tyrosine phosphorylated by Jak2, resulting in inhibition of phosphatase activity. 
Interaction of PP2A and Stat5 tends to result in decreased tyrosine phosphorylation and 
decreased nuclear translocation of Stat5 (Yokoyama et al., 2001). 
As discussed earlier nuclear export of STAT proteins is dependent on tyrosine 
dephosphorylation, which leads to the accessibility of the NES by CRM1 and the nuclear 
export of STAT proteins. Potential nuclear phosphatases for STAT dephosphorylation are 
SHP2 for Stat1 (Wu et al., 2002) and the nuclear isoform of TC-PTP (TC45) for Stat1 
and Stat3. Embryonic fibroblasts (MEFs) that lack TC45 fail to dephosphorylate IFN 
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 induced tyrosine-phosphorylated Stat1 and dephosphorylation of Stat3, but not Stat5 or 
Stat6, is also affected (Haspel and Darnell, 1999; ten Hoeve et al., 2002) In the contrary 
overexpression of TC45 results in dephosphorylation of Stat3, Stat5a and Stat5b (Aoki 
and Matsuda, 2002; Yamamoto et al., 2002). The identification of further PTPs that are 
involved in dephosphorylating specific STATs in the nucleus will be of great interest. 
Stat1, Stat3 and Stat5 TC45 
Stat1 SHP2 
Targets nuclear tyrosine phosphatases 
JAK2 PTP-PEST 
JAK2, TYK2 and Stat5 PTP1B  
JAK1, JAK3 TC-PTP  
JAK1 and TYK2 PTPεC  
All JAKs CD45 
JAK1 and Stat5 SHP2 
JAK1 and JAK2 SHP1 
Targets cytoplasmic tyrosine phosphatases 
 
Table 6: Cytoplasmic and nuclear tyrosine phosphatases of the JAK/STAT pathway 
The SOCS family of inhibitors 
The suppressors of cytokine signaling (SOCS) are a family of intracellular proteins that 
play a crucial role in negatively regulating the response of the immune system to 
cytokines. These inhibitors have been variously named by independent discoverers as 
suppressor of cytokine signalling (SOCS), JAK-binding proteins (JABs), STAT-induced 
STAT inhibitors (SSIs) or cytokine-induced SH2 (CIS) proteins. The eight proteins that 
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 belong to the SOCS family include cytokine-inducible SH2 domain protein (CIS) and 
SOCS1-SOCS7. SOCS proteins contain a central SH2 domain, an amino-terminal 
domain of variable length and a divergent sequence that carries in the case of SOCS1 and 
SOCS3, a kinase inhibitory region and a carboxy-terminal 40 amino-acid module known 
as the SOCS box (Fig. 12) (Krebs and Hilton, 2000). The SOCS box can bind to elongins 
B and C, which are known components of a ubiquitin E3 ligase complex suggesting that 
SOCS proteins may target signaling molecules like JAK2, to the proteasome for 
degradation (Kamura et al., 1998; Ungureanu et al., 2002; Zhang et al., 1999a). 
Interestingly, Kamizone et al. demonstrated that the SOCS box of SOCS1 interactes with 
Cullin-2 and promotes ubiquitylation of TEL-JAK2 (Kamizono et al., 2001). 
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Fig. 12: Domain structure of SOCS. Red arrow: variable N-terminal domain; K: 
kinase inhibitory region. Adapted from (Krebs and Hilton, 2000). 
SOCS proteins are generally expressed at low levels in unstimulated cells and expression 
is largely increased upon cytokine, insulin and EGF stimulation (Alexander, 2002; Endo 
et al., 1997; Naka et al., 1997; Starr et al., 1997). The fact that they subsequently inhibit 
JAK/STAT signaling leads to the conclusion that they act as classical feedback loop 
inhibitors (Matsumoto et al., 1997; Yoshimura et al., 1995). Posttranslational 
modifications of SOCS3 have also been shown after stimulation with cytokines and 
growth factors. SOCS3 becomes Tyr phosphorylated at Y204 and Y221, in the conserved 
SOCS box, by JAKS and other receptor tyrosine kinases (Cohney et al., 1999). Haan et 
al. showed that phosphorylation of SOCS3 at Y204 and Y221, inhibits the SOCS3-
elongin C interaction and activates proteasome-mediated SOCS3 degradation. Mutation 
of these two tyrosines lead to stabilization of SOCS3 (Haan et al., 2003). This suggests 
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 that cytokines are regulating JAK/STAT feedback inhibition via two conflictive ways; 
upregulation of SOCS proteins and increasing the degradation of SOCS proteins.  
The mechanism of inhibition varies between the different SOCS proteins (Fig: 13). 
SOCS1 binds directly via its SH2 domain to tyrosine phosphorylated JAKs, as a 
consequence JAK activity is directly inhibited. SOCS3 uses a different mechanism for 
inhibition of JAKs, it binds to the activated receptor directly (Nicholson et al., 1999; 
Sasaki et al., 1999). Binding to gp130 occurs at the Y759 motif that also binds SHP2 (De 
Souza et al., 2002; Nicholson et al., 2000; Schmitz et al., 2000b). With the help of 
experiments allowing the recruitment of only SHP2 or SOCS3 to gp130 the independent 
negative regulatory function of each inhibitor has been shown, suggesting that SHP2 and 
SOCS3 trigger two distinct inhibitory mechanisms (Lehmann et al., 2003). CIS does not 
affect the activity of JAKs, compared to SOCS1 and SOCS3, it competes with STATs for 
binding sites at the receptor and therefore inhibits STAT phosphorylation (Verdier et al., 
1998).  
 
Fig. 13: Inhibition of JAK/STAT pathway by SOCS proteins. Adapted from (Shuai 
and Liu, 2003) 
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 Gene targeting studies demonstrated the essential function of the SOCS proteins in the 
regulation of the immune system (Table 7) (Krebs and Hilton, 2000; Levy and Darnell, 
2002).  
 
Embryonic lethality, placental and hematopoietic defects. SOCS3 
Gigantism due to dysregulated growth hormone and Igf1 signaling.SOCS2 
Perinatal lethality, IFN-γ-overproduction, liver degeneration, 
hypersensitivity to LPS, increased apoptosis in lymphoid organs. 
SOCS1 
Normal Cis 
Phenotype of null mice Gene 
Table 7: Effects of SOCS proteins as shown in knockout mice. Adapted from (Levy 
and Darnell, 2002). 
Conditional gene targeting studies to generate mice lacking SOCS3 in macrophages 
showed that the SOCS proteins have specificity for cytokines but not for JAKs or STATs. 
For example, Stat3 activation was prolonged after IL-6 stimulation but not after 
stimulation with IL-10, which both activate Stat3, in SOCS3 -/- macrophages, illustrating 
a new specificity for SOCS3 mainly targeting gp130 dependent signaling pathways 
(Croker et al., 2003; Lang et al., 2003; Yasukawa et al., 2003).  
The PIAS family of inhibitors 
Five members belong to the family of proteins that inhibit activated STAT (PIAS) 
PIAS1, PIAS3, PIASxα, PIASxβ and PIASy. A RING-finger-like zinc-binding domain 
(RLD) in the central region of PIAS is the most conserved domain. In addition they have 
a highly acidic region, which carries a putative small ubiquitin-related modifier1 
(SUMO1) interaction motif (SIM), a serine/threonine  (S/T) region at the C-terminus as 
well as a SAP (scaffold attachment factor A and B) domain at the N-terminus (Fig. 14). 
The SAP domain mediates interactions between nuclear receptors and their co-regulators. 
PIASy does not bear the SIM motif nor the S/T region.  
 36
 SAP 
domain 
RLD 
domain 
Acidic 
domain 
S/T 
domain 
N S C 
 
Fig. 14: Domain structure of PIAS. S: SIM motif. 
PIAS1 has first been identified by yeast two-hybrid screens with Stat1β as a bait (Liu et 
al., 1998). The authors also identified PIAS1 as a novel negative regulator of Stat1 that 
blocks DNA-binding and consequently inhibits Stat1 mediated transcriptional activity 
after IFN stimulation. The inhibitory effect was specific for Stat1 and required interaction 
of PIAS1 with the Stat1 dimer, but not unphosphorylated Stat1 monomer (Liao et al., 
2000; Liu et al., 1998). The specific regions for interaction are a region near the C-
terminus of PIAS1 (amino acids 392-541), which interacts with the N-terminus (amino 
acids 1-191) of Stat1 (Liao et al., 2000). Interaction of PIAS1 to methylated Stat1 is 
reduced as described under “Posttranslational Modifications of STAT proteins” (Mowen 
et al., 2001).  
PIAS3 was found via searching of the expressed sequence tag (EST) database for other 
members of the family and showed to be an inhibitor of IL-6 activated Stat3 or prolactin 
activated Stat5 (Chung et al., 1997a; Rycyzyn and Clevenger, 2002). The mechanism of 
inhibition is identical to the mechanism of PIAS1 inhibition of Stat1 also requiring Stat3 
phosphorylation. The zinc finger protein Gfi-1 is able to rescue the PIAS3 induced 
inhibition of Stat3 via direct interaction with PIAS3, though the exact mechanism is not 
known (Rodel et al., 2000). Interestingly PIAS1 as well as PIAS3 have been shown to 
enhance the transcriptional activity of androgen receptor (AR), while PIASy on the other 
hand repressed AR-mediated gene activation in prostate cancer cells (Gross et al., 2001). 
Other members of the family have been found to inhibit STATs, PIASy inhibits Stat1 and 
PIASx inhibits Stat4 after IFN or IL-12 stimulation, respectively (Arora et al., 2003; Liu 
et al., 2001). However, DNA binding activity of Stat1 or Stat4 is not changed (Arora et 
al., 2003; Liu et al., 2001). In fact, PIASx is present in the DNA-binding complex and the 
inhibitory activity of PIASx on Stat4 mediated gene activation is eliminated by the 
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 histone deacetylase inhibitor trichostatin A (TSA) (Arora et al., 2003). Other evidence for 
the importance of histone deacetylases (HDACs) in the PIAS induced mechanism comes 
from the description of association of PIAS with HDAC molecules; PIASxβ associates 
with HDAC3 and PIASy interacts constitutively with HDAC1 (Long et al., 2003; Tussie-
Luna et al., 2002). A further characteristic of PIAS proteins is that they exhibit E3-small 
ubiquitin-related modifier (SUMO) ligase activity (Johnson and Gupta, 2001; Kotaja et 
al., 2002; Sachdev et al., 2001; Schmidt and Muller, 2002).  
Similar to ubiquitylation, sumoylation, the covalent attachment of SUMO to its substrate, 
requires a set of enzymes (E1-E3) for its conjugation to the target that are different from 
the enzymes acting on ubiquitin. The SUMO E1 activating enzyme is a heterodimer 
composed of the proteins Aos1 and Uba2, whereas the ubiquitin E1 is a single protein, 
Uba1. Furthermore, sumoylation requires only one E2 conjugating enzyme Ubc9, 
compared to the vast number of E2 enzymes available in the ubiquitin pathway. The 
ligating E3 enzyme, which performs an adaptor function between the E2 enzyme and the 
substrate, has recently been identified as PIAS, RAN-binding protein 2 (RanBP2) or the 
polycomb protein (PC2). The E3 enzymes are all sumoylated themselves. All proteins, 
which are targeted for sumoylation share a common motif, a short consensus sequence, 
the ΨkxE motif. Lastly, Ulp is a protein that has a dual function in maturation of the 
SUMO pre-protein and in the removal of SUMO from the target (Fig. 15) (Seeler and 
Dejean, 2003).  
Sumoylation influences various processes, for example, subcellular localization or 
prevention of ubiquitylation of the substrates. Protein targeting effects of SUMO imply 
nuclear import or export as well as sequestration of transcription factors to specific 
cellular compartments. Both functions have been observed with the transcriptional 
repressor TEL, which will be discussed later. 
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Fig. 15: The SUMO pathway. Adapted from (Seeler and Dejean, 2003) 
As mentioned above, it was previously known that PIAS proteins exhibit E3 SUMO 
ligase activity but it has been shown only in recent times that Stat1 is sumoylated by 
PIAS family members. Sumoylation occurs at a single, evolutionary conserved amino 
acid residue, lysine 703, and mutation of this lysine abolishes sumoylation. The function 
of sumoylation is not clear since Rogers et al. do not see an effect on Stat1 activation 
while other experiments show an increase in IFN stimulated Stat1 activation after 
sumoylation (Rogers et al., 2003; Ungureanu et al., 2003). Taken all results together this 
data implies that the mode of inhibition of STAT proteins via the PIAS family can 
include different ways via reduced DNA-binding (Fig. 16a), by recruitment of histone 
deacetylases (HDAC) to the transcription complex (Fig. 16b), or via sumoylation  (Fig. 
16c). Further studies will be necessary to completely unravel the mechanisms by which 
different members of the PIAS proteins are able to negatively regulate the STAT 
signaling pathways. 
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Fig. 16: Possible mechanisms for inhibition of the JAK/STAT signaling pathways by 
PIAS. Adapted from (Shuai and Liu, 2003) 
STAT interacting proteins (co-activators) 
It becomes increasingly clear that transcription factors rarely operate alone, but rather 
work together with other transcription factors or co-activators to enhance or repress each 
other. Most transcription factors interact with histone acetyltransferases (HATs) 
enzymes, which link acetyl groups to histones, and co-activators. The TADs of Stat1, 
Stat2, Stat3, Stat5 and Stat6 interact with the CREB-binding protein (CBP/p300) (Hiroi 
and Ohmori, 2003; Paulson et al., 1999; Pfitzner et al., 1998; Zhang et al., 1996); STAT2 
recruits in addition the HAT protein general control nonrepressed 5 (GCN5) through its 
TAD (Paulson et al., 2002). Recruitment of HATs results in localized transient 
acetylation of histones and the enhancement of activator-dependent transcriptional 
activity. The association of Stats and CBP/p300 is further enhanced by the N-Myc 
interactor (Nmi) protein, which interacts with all STATs except Stat2. Nmi amplifies 
STAT-mediated transcription in cells stimulated with IL-2 and IFNγ (Zhu et al., 1999). In 
addition, associations have been shown between: Stat1 and mini-chromosome 
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 maintenance5 (MCM5), ubiquitous factor1 (USF1), SP1, BRCA1, PU.1 and 
glucocorticoid receptor (GR) (Aittomaki et al., 2000; Look et al., 1995; Muhlethaler-
Mottet et al., 1998; Ouchi et al., 2000; Zhang et al., 1998); Stat5 and GR, Sp1, and 
C/EBPβ (Martino et al., 2001; Stocklin et al., 1996; Wyszomierski and Rosen, 2001); and 
Stat6 with C/EBPβ, p100, and NCoA-1 (Litterst and Pfitzner, 2001; Mikita et al., 1998; 
Yang et al., 2002b).  
Stat3’s transcriptional activity is enhanced by CBP/p300, Nmi, forkhead transcription 
factor (FKHR), c-Jun, SP1, and EZI and repressed by Tip 60 (Cantwell et al., 1998; 
Kortylewski et al., 2002; Schaefer et al., 1995; Xiao et al., 2003; Zhang et al., 1999b).  
Biological function of STATs 
Gene-targeting studies indicate that some STAT proteins are highly specific in their 
function and that they are responsible for mediating the immune response in mammals 
(Table 8).  
Embryonic lethal, impaired cell survival, impaired response to 
pathogens 
Stat3 
Viable and fertile, defective IFNα/β signaling  Stat2 
Viable and fertile, defective IFNα/β and IFNγ signaling, 
defective immune response, increased tumorigenicity 
Stat1 
Viable and fertile, defective IL-4 signaling, impaired Th2 
differentiation 
Stat6 
Viable and fertile, defective growth hormone signaling, 
impaired growth 
Stat5b 
Viable and fertile, defective prolactin signaling, impaired 
mammary gland development 
Stat5a 
Viable and fertile, defective IL-12 signaling, impaired Th1 
differentiation 
Stat4 
Phenotype of null mice Gene 
 
Table 8: Phenotype of STAT knockout mice. Adapted from (O'Shea et al., 2002). 
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 Stat1 
Stat1 knockout mice are viable and fertile and display no developmental defects. 
However, Stat1-/- mice failed to induce transcription of target genes after simulation with 
IFNα/β and IFNγ; these mice are highly susceptible to microbial and viral infections 
(Durbin et al., 1996; Meraz et al., 1996). Atypical susceptibility to mycobacterial but not 
to viral infection has also been identified in patients suffering with a natural heterozygous 
germline Stat1 mutation, further strengthening the importance of Stat1 in contributing to 
immune responses (Dupuis et al., 2001). Interestingly, Stat1 deficient mice also showed 
sensitivity for both spontaneous tumor development and tumor development after 
methylcholanthrene treatment (Kaplan et al., 1998; Shankaran et al., 2001). This suggests 
that Stat1 has a proapoptotic function.  
Stat2 
Stat2 is an exceptional member of the STAT family, since it does not bind to GAS 
elements and it does not homodimerize. Instead, upon activation by IFNα Stat2 forms, 
the transcription factor complex ISGF3, together with Stat1 and p48/ISGF3gamma. 
Therefore, it is no surprising that the Stat2 knockout exhibits similarities with the Stat1 
knockout. The mice are viable, fertile and display no developmental defects. 
Nevertheless, they are also susceptible to viral infections due to their impaired ability to 
respond to IFNα/β signaling. Additionally, Stat1 tyrosine phosphorylation and activation 
after IFNα stimulation is weakened in the Stat2 deficient mice, arguing for an enhancer 
effect of Stat2 in binding to the receptor complex in the Stat1/Stat2 heterodimers (Park et 
al., 2000a). 
Stat3 
Will be discussed in detail in the section Stat3. 
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 Stat4 
Stat4 is only expressed in natural killer cells (NK cells), dentritic cells and T lymphocytes  
and is mainly activated by IL-12. CD4+ T cells differentiate with the help of IL-12 to Th1 
cells, which in turn leads to the expression of IFNγ.  Th1 cells are involved in host 
defense against intracellular pathogens and tumors, and in the development of 
autoimmune diseases, for example, rheumatoid arthritis, diabetes and multiple sclerosis. 
Consequently it was no surprise that the Stat4 and IL-12 deficient mice show a similar 
phenotype, i.e., loss of Th1 differentiation, loss of IFNγ expression and enhanced 
tendency towards Th2 differentiation, which is usually inhibited by Th1 cells (Kaplan et 
al., 1996b; Thierfelder et al., 1996). Recent data indicate that Stat4 deficient mice show a 
resistance to autoimmune diseases like rheumatoid arthritis, diabetes and experimental, 
allergic encephalomyelitis (EAE) (Chitnis et al., 2001). In humans, it was shown that 
IFNα/β can stimulate T cells to drive Th1 development, bypassing the need for IL-12-
induced signaling, in contrast IFNα does not cause Th1 differentiation in mice (Rogge et 
al., 1998). The reason for this is that IFNα/β is able to activate Stat4, by recruitment of 
Stat4 to the IFNα receptor complex exclusively via the C-terminus of Stat2 in human 
cells. The difference between mouse and human signaling is that the mouse Stat2 gene 
harbors a minisatellite insertion, which change the C-terminus sequence and selectively 
disrupte its ability to activate Stat4, but not other STATs (Farrar et al., 2000).  
Stat5 
Stat5 was originally characterized as a prolactin-responsive transcription factor in sheep 
and exists as two closely related genes, Stat5a and Stat5b, which share 95 % identity at 
the N-terminus and some variability at the C-terminus (Azam et al., 1995; Mui et al., 
1995). Both genes are expressed in all tissues and are activated by a wide variety of 
cytokines. Given the broad range of activation one might think that the knockout of these 
proteins would have many effects. However, the Stat5 specific knockouts exhibited a 
very precise phenotype for the individual gene. Both of the Stat5a and Stat5b deficient 
mice are viable, fertile and displaye no developmental defects. Stat5a -/- mice are 
impaired in prolactin activated mammary gland development, necessary for lactation (Liu 
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 et al., 1997; Teglund et al., 1998), while Stat5b -/- mice have impaired GH signaling 
effects, similar to GH deficient mice (Teglund et al., 1998; Udy et al., 1997). Since high 
GH levels are mainly observed in males, female Stat5b -/- showed almost no phenotype 
while males were smaller and revealed the loss of male-specific liver genes (as MUP and 
CYP2D9). Interestingly the Stat5a/b double knockout mice are infertile, small, die after a 
few weeks of birth, and are defective in the development of the mammary gland and the 
corpus luteum (Teglund et al., 1998).  
Stat6 
Stat6 is ubiquitously expressed and is mainly activated by IL-4 and IL-13 (Kisseleva et 
al., 2002). IL-4 is expressed by activated T and B cells and regulates differentiation of 
CD4+ T cells to Th2 cells and class switching of B cells resulting in secretion of IgE. Th2 
helper cells are essential for host defense against helminthes and further allergic 
responses. Stat6 and IL-4 deficient mice show similar phenotypes; neither they are able to 
differentiate into Th2 cells and they are inoperative to class switch to IgE; otherwise they 
are viable, fertile and display no developmental defects (Kaplan et al., 1996a; Shimoda et 
al., 1996; Takeda et al., 1996). In addition, Stat6 deficient mice, have a predominantly 
Th1 phenotype, experience a severe clinical course of EAE, are inhibited in host defense 
against helminthes, are resistant to septic peritonitis because of enhanced local bacterial 
clearance, show resistance to tumor recurrence and deregulated activation of NF-κB 
leading to reduced expression of proinflammatory cytokines and chemokines induced by 
endotoxins (Chitnis et al., 2001; Lentsch et al., 2001; Matsukawa et al., 2001; Terabe et 
al., 2000). 
STATs and cancer  
Constitutively activated Stat1, Stat3 and Stat5 proteins have been observed in a wide 
variety of human cancer cell lines as well as primary tumors, which is probably due to 
dysregulation of STAT activators or mutations and loss of proteins that negatively 
regulate STAT proteins, since mutations in STATs leading to constitutively active 
proteins have not been reported yet (Table 9). 
 44
 Stat3 Ovarian carcinoma 
Stat3 Pancreatic adenocarcinoma 
Stat3 Melanoma 
Stat3 Prostate carcinoma 
Stat3 Renal cell carcinoma 
Stat1, Stat3 Lung cancer 
Stat3 Lymphoma 
Stat1, Stat3, Stat5 Chronic myelogenous leukemia 
(CML) 
Stat1, Stat3, Stat5 Acute myelogenous leukemia (AML)
Stat1, Stat3, Stat5 Chronic lymphocytic leukemia (CLL)
Stat1, Stat5 Acute lymphocytic leukemia (ALL) 
Stat1, Stat3 Head and neck cancer 
Stat1, Stat3 Multiple myeloma 
Stat1, Stat3, Stat5, Stat6 Breast Cancer 
Activated STAT Tumor Type 
 
Table 9: Activation of STATs in human cancers. Adapted from (Bowman et al., 
2000). 
As discussed earlier Stat1 is considered a tumor suppressor, since mice lacking Stat1 are 
more susceptible to chemically induced primary tumors and to transplanted tumors 
(Kaplan et al., 1998; Lee et al., 2000a; Lee et al., 2000b; Shankaran et al., 2001). 
Furthermore, Stat1 is essential for cell growth suppression in response to IFN-gamma and 
EGF, partly by inducing cyclin dependent kinase (cdk) inhibitor p21 WAF1/CIP1 in 
response to cytokines, this involves BRCA1, which is often lost in breast cancer 
(Bromberg et al., 1998a; Bromberg et al., 1996; Chin et al., 1996; Ouchi et al., 2000). 
The fact that several tumors show constitutively active Stat1 suggest that Stat1 activation 
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 is part of the host’s tumor surveillance capability and it will be of interest to study if Stat1 
is mutated in some human tumors.  
Stat5 is mainly activated in leukemias and lymphomas and it was shown by expression of 
a dominant negative form of Stat5 that active Stat5 is necessary for the growth of 
hematopoietic cells, myeloid precursor cells and leukemia cells transformed by the BCR-
Abl oncogene (de Groot et al., 1999; Nieborowska-Skorska et al., 1999; Sillaber et al., 
2000). However, recent data, which was obtained with Stat5 deficient bone marrow 
derived B cells, shows that Stat5 is essential for TEL-JAK2 induced tumors, but not for 
v-Abl or BCR-ABL dependent transformation (Schwaller et al., 2000; Sexl et al., 2000). 
It therefore plays a critical role in the development of TEL-JAK2 induced leukemias and 
lymphomas but not, as suggested before, in v-Abl or BCR-ABL dependent 
transformation. In addition, Stat5 is able to induce expression of antiapoptotic signaling 
proteins for example Bcl-xl (Calo et al., 2003). The role of Stat3 in cancer will be 
discussed in the next section. 
Stat3 
Stat3 was initially identified as the acute-phase response factor (APRF), activated by IL-6 
(Wegenka et al., 1993). The authors further showed that Stat3 activation occurred in the 
cytoplasm, that Stat3 phosphorylation is essential and that Stat3 binds to IL-6 response 
elements of various acute-phase protein genes (e.g., the alpha 2-macroglobulin, 
fibrinogen, and alpha 1-acid glycoprotein genes) (Wegenka et al., 1993). The Stat3 
cDNA was cloned one year later and encodes an open reading frame of 770 amino acids 
resulting in a protein of 88 kDa (Akira et al., 1994). Stat3 is ubiquitously expressed and 
expression starts very early during post-implantation development in the mouse. Stat3 
can be activated by many different cytokines, growth factors and oncogenes (Fig.4). The 
IL-6 family of cytokines has many biological functions and Stat3 plays a major role in 
these processes (Hirano et al., 2000). IL-6 activation in mouse myeloid leukemia M1 
cells has been shown to lead to growth arrest and terminal differentiation into 
macrophages. Overexpression of Stat3DN abrogated the IL-6 induced effects and 
resulted in inhibition of IL-6-induced repression of c-myb and c-myc (Minami et al., 
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 1996; Nakajima et al., 1996). These experiments demonstrated for the first time that Stat3 
activation is essential for IL-6 mediated growth arrest. Conversely, Fukada et al. found 
that Stat3 is involved in anti-apoptosis, proliferation and upregulation of Bcl-2 by 
overexpression of Stat3DN in mouse pro-B (BAF/B03) cells (Fukada et al., 1996). The 
authors demonstrated in the following years that Stat3 activation was not only essential 
for cell survival but also required for cell cycle transition, via Stat3 mediated 
upregulation of cyclins D2, D3 and A, and cdc25A, and the associated downregulation of 
p21 and p27 (Fukada et al., 1998). 
OSM and ciliary neurotrophic factor (CNTF) promote differentiation of cerebral cortical 
precursor cells or cultured fetal mouse neuroepithelial cells into astrocytes. 
Overexpression of Stat3DN completely blocked OSM induced promoter activation of the 
gene for an astrocyte marker, glial fibrillary acidic protein (GFAP) (Bonni et al., 1997; 
Yanagisawa et al., 1999). Moreover, expression of GFAP was severely reduced in the 
brain of gp130 -/- mice as well as in mice expressing a mutant gp130, which is defective 
in Stat3 signaling but not in SHP2 signaling (Nakashima et al., 1999; Ohtani et al., 2000). 
The mice that express a mutant gp130 helped also to understand the mechanism of B cell 
differentiation into antibody-forming plasma cells, since mice harboring a construct 
lacking the tyrosines of gp130 important for Stat3 activation, showed decreased IgG2a 
and IgG2b production (Ohtani et al., 2000). Another receptor that is capable of inducing 
B cell differentiation is CD40, which lacks intrinsic tyrosine kinase activity, but is still 
able to induce tyrosine phosphorylation and activation of constitutively associated JAK3, 
as well as of Stat3. Mutation of the JAK3 binding domain inhibits B cell differentiation 
(Hanissian and Geha, 1997). Taken these results into consideration one has to argue that 
Stat3 is involved in astrocyte and B cell differentiation.  
Interestingly, in a few cases Stat3 is also able to inhibit cell differentiation, following its 
activation with IL-6 or LIF. IL-6 was shown to induce differentiation of PC12 cells that 
have been pretreated with nerve growth factor (NGF). Stimulation of the MAPK pathway 
is important for neurite outgrowth, since cells overexpressing gp130 mutants incapable of 
activating the MAPK cascade or cells treated with the MEK inhibitor PD98059 treatment 
with IL-6 failes to induce differentiation of PC12. Conversely, overexpression of a 
 47
 mutant gp130, which is defective in Stat3 signaling but not in SHP2 signaling, did not 
inhibit, but rather stimulated neurite outgrowth. NGF pretreatment inhibited the IL-6-
induced activation of Stat3 and overexpression of Stat3DN did not require NGF 
pretreatment for neurite outgrowth. These facts indicate that Stat3 is negatively involved 
in PC12 differentiation (Ihara et al., 1997). Likewise, Stat3 is essential for self renewal of 
embryonic stem (ES) cells, that are continuously propagated in an undifferentiated 
pluripotent state with LIF, since overexpression of a dominant negative Stat3 is able to 
abrogate LIF mediated self-renewal and promotes differentiation (Boeuf et al., 1997; 
Niwa et al., 1998; Raz et al., 1999). Concordant with this finding is a study of ES cells 
expressing a fusion protein composed of the entire coding region of STAT3 and the 
ligand binding domain of the estrogen receptor (Stat3ER) that can be activated by the 
synthetic ligand 4-hydroxytamoxifen (4HT), maintained an undifferentiated state upon 
stimulation with 4HT (Matsuda et al., 1999).  
Stat3 conditional gene targeting in mice 
Stat3 is the only STAT family member whose knockout leads to embryonic lethality. 
Stat3 deficient mice develop into the egg cylinder stage but show a rapid degeneration 
between embryonic days 6.5 and 7.5. This is probably due to nutritional insufficiency, 
since Stat3 is expressed at day 7.5 in the embryonic visceral endoderm, which is 
important for nutrient exchange between the maternal and embryonic environment 
(Takeda et al., 1997). Some knockouts of components of Stat3 activating pathways also 
lead to embryonic lethality, such as gp130 and LIFRβ. However, none of the known 
activating cytokines or growth hormones or JAKs function so early in development. So, 
the early lethality as well as the Stat3 activating cascade during early development 
remains an enigma up to date. Nevertheless, with the use of the Cre-lox technology, 
which allows targeting of Stat3 -/- to any desired embryonic or adult tissue, it has became 
possible to generate tissue specific knockouts (Table 10).  
 48
 Stat3-deficient T cells showed a loss of proliferative response due to a defect in IL-6 
mediated prevention of apoptosis. The antiapoptotic protein, Bcl-2, is normally 
upregulated in response to IL-6 even in Stat3-deficient T cells (Takeda et al., 1998). This 
suggests that Stat3 has a Bcl-2 independent anti-apoptotic function  
Enhanced inflammatory response, chronic colitis and Th1 
differentiation 
Monocytes 
/Neutrophils 
Higher sensitivity to inflammation, cardiac fibrosis and 
heart failure with advanced age 
Cardiomyocyte 
Enhanced neuronal apoptosis, impaired survival after 
nerve damage 
Neurons 
Impaired acute-phase response Liver 
Impaired second hair cycle, wound repair and 
keratinocyte migration 
Skin 
Decrease in apoptosis, delayed mammary involution Mammary 
epithelium 
Viable and fertile, defective growth hormone signaling, 
impaired growth 
Granulocytes 
Age-dependent thymic hypoplasia, hypersensitivity to 
stress 
Thymic 
epithelium 
Impaired IL-6 dependent survival, impaired IL-2Rα 
expression 
T lymphocytes 
Phenotype of null mice Target 
tissue 
 
Table 10: Phenotypes of tissue-specific knockout of Stat3. Adapted from (Levy and 
Darnell, 2002). 
Targeted Stat3 knockout in macrophages and neutrophils results in mutant mice that are 
highly susceptible to endotoxin shock and develop chronic enterocolitis with age, due to 
abolished inhibitory effects of IL-10 on inflammatory cytokine production (Takeda et al., 
1999). In addition, Stat3 -/- plus IL-10 -/- mice show similar phenotypes and it has been 
shown that IL-10 suppresses expression of TNF-α via Stat3 (Riley et al., 1999). 
 49
 Stat3 phosphorylation occurs at the onset of mammary gland involution and Stat3 null 
mammary glands show a decrease in apoptosis and a dramatic delay of involution, a stage 
of mammary gland development that is characterized by extensive apoptosis of the 
epithelial cells. In normal glands involution is accompanied by increase in insulin-like 
growth factor binding protein (IGFBP5) levels, which binds the survival factor insulin-
like growth factor (IGF1) and inhibits IGF1. There is evidence to suggest that IGFBP-5 is 
a direct or indirect target for Stat3 since IGFBP5 upregulation is not observed in Stat3 
null mammary glands (Chapman et al., 1999). These data showed for the first time that 
Stat3 is important for apoptosis in vivo.  
Mice with Stat3 deficient epidermal and follicular keratinocytes were viable and did not 
have any defects in the development of epidermis and hair follicles. However, the mice 
had sparse hair, wound-healing processes were severely impaired and they spontaneously 
developed ulcers with age. Considering that migration and proliferation are essential for 
wound healing, motility and growth of keratinocytes was examined. Results illustrated 
that migration of Stat3-disrupted keratinocytes in response to growth factor stimulation, 
in vitro, was impaired while proliferation was not disturbed. Furthermore, the mice 
exhibited a normal first hair cycle (morphogenesis), but an impaired second hair cycle 
(skin remodeling) (Sano et al., 1999). This analysis provided the first in vivo data 
showing that Stat3 has a function in cell migration and that Stat3 is necessary for skin 
remodeling, including hair cycle and wound healing.  
Activation of Stat3 in the brain functions via CNTF and leptin and inactivation of Stat3 in 
cytokine-dependent sensory neurons of the nodose ganglion reduced the response of 
these neurons to CNTF and LIF and enhanced their death after nerve lesion (Alonzi et al., 
2001b; Schweizer et al., 2002). Knockout of Stat3 in cardiomyocytes showed that Stat3 is 
involved in regulation of inflammatory responses and survival (Jacoby et al., 2003). Stat3 
deficient hepatocytes severely impaired IL-6 induced acute-phase response in the liver 
during inflammation (Alonzi et al., 2001a). Interestingly, Stat3β deficient mice exhibited 
reduced recovery from endotoxic shock and showed hyperresponsiveness to a subset of 
endotoxin-inducible genes in liver. These findings reveal a critical negative regulatory 
role for Stat3β in the control of systemic inflammation (Yoo et al., 2002). Considering all 
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 knockout data together it is surprising that Stat3 has such mild phenotypes in the 
conditional knockout mice compared to the early embryonic lethality in the full 
knockout. The data suggests that the Stat3 activators in early development are different 
from the known activators in the adult and it will be of interest to identify them. 
Moreover, Stat3 elicits diverse functions in various cell types since the readout of the 
Stat3 tissue deficient mice is diverse and ranges from apoptosis, survival, and effects on 
migration up to proliferation. It will be a challenge to solve the riddle why Stat3 
activation has diverse biological functions and the more information we are able to gain 
about the different sets of genes that are regulated by Stat3, in different cell types, the 
more we will be able to understand the function of the Stat3 molecule. 
Stat3 specific negative regulator GRIM-19 
Gene associated with retinoid-interferon-induced mortality-19, (GRIM-19) is essential 
for tumor cell death induced by interferon-beta (IFN-beta) and retinoic acid (RA) (Angell 
et al., 2000). Since GRIM-19 is localized on human chromosome 19p13.2., a region that 
is essential for prostate tumor suppression, it was speculated that GRIM-19 might be a 
novel tumor suppressor (Chidambaram et al., 2000). The cellular localization as well as 
the domain structure of GRIM-19 is unclear. The interaction of GRIM-19 and Stat3 was 
first observed via yeast two-hybrid screening and is specific for Stat3, since GRIM-19 did 
not interact with Stat1 and Stat5. GRIM-19 inhibits Stat3 transcriptional activation 
stimulated by EGF or IL-6 (Lufei et al., 2003; Zhang et al., 2003b). Lufei et al. 
demonstrated that the coiled-coil region of Stat3 is able to bind to GRIM-19 and is 
involved in the formation of aggregates with GRIM-19. It was also suggested that GRIM-
19 inhibits Stat3 by blocking nuclear translocation of Stat3 (Lufei et al., 2003). Zhang et 
al. however, showed that the TAD domain of Stat3 is important for GRIM-19 binding 
and inhibition. They did not see any change in Stat3 nuclear localization and DNA-
binding in cells overexpressing GRIM19 and therefore argue against the model of Lufei 
et al. (Zhang et al., 2003b). The mechanism of inhibition of Stat3 by GRIM19 has 
therefore to be investigated further to draw a final conclusion. 
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 Stat3 specific negative regulator TIP60 
Tat-interactive protein 60kDa (Tip 60) belongs to the MYST family of HAT proteins, a 
family that is highly conserved from yeast to mammals. Expression of Tip60 can be 
observed in a wide variety of tissues and cell lines. Tip 60 is mainly localized to the 
nucleus where it forms stable nuclear complexes possessing ATPase and HAT activity 
for histones H4, H3 and H2A. The Tip 60 structure bears two important domains a 
chromatin organization modifier (CHROMO) domain at the N-terminus and a MYST 
('MOZ, Ybf2/Sas3, SAS2 and Tip60', where MOZ stands for male absent on the first, 
SAS for something about silencing and Ybf2 for identical with SAS2) region at the C-
terminus (Sterner and Berger, 2000). Recent results indicate that Tip60 interacts with 
Stat3 and represses Stat3 transcriptional activity, since overexpression of Tip60 repressed 
Stat3 reporter gene expression. The authors showed further that Tip60 interacts as well 
with HDAC7 and that HDAC7 activity is necessary to inhibit Stat3 activity (Xiao et al., 
2003). 
Stat3 function in human disease 
 
Crohn's disease is a chronic inflammatory bowel disease of the gastrointestinal tract of 
poorly known etiology. Through the studies of patients and mouse models, it was shown 
that the disease occurs as the consequence of a deregulated immune response to normal 
components of the intestinal flora in a genetically predisposed host. Two recent 
publications demonstrate that Stat3 might have critical roles in the development and 
regulation of innate immunity leading to Crohn's disease. First, tissue-specific disruption 
of STAT3 in bone marrow cells during hematopoiesis, causes death of the mice within 4-
6 weeks after birth with Crohn's disease-like pathogenesis (Welte et al., 2003). Second, in 
a study of intestinal T cells from Crohn's disease and healthy volunteers it was 
demonstrated that STAT3 and STAT4 are constitutively activated in Crohn's patients, but 
not in healthy volunteers. (Lovato et al., 2003). Nevertheless, the mechanism whereby 
Stat3 contributes to Crohn's disease pathology is not known. 
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 Stat3 in cancer 
As mentioned earlier Stat3 is constitutively activated in a wide variety of human tumors 
(Table 9), this activity is attributed to dysregultion of cytokine receptors, growth factors 
receptors and aberrant JAK activity. For example, the upregulation of TGFα and EGFR 
activates Stat3 in squamous cell carcinoma of the head and neck (SCCHN) (Song and 
Grandis, 2000). Furthermore, Stat3 is also constitutively activated by oncogenes such as 
v-abl, v-src, v-fps, v-sis, v-ros, and v-eyk (Bowman et al., 2000; Yu et al., 1995). 
Overexpression of Stat3DN, Stat3β, the use of Stat3 antisense oligonucleotides or a Stat3 
decoy oligonucleotide has proven to be valid tools to examine the function of 
constitutively activated Stat3 in a large number of cancer cell lines or tumors. For 
example, it has been demonstrated by overexpression of Stat3DN that Stat3 activity is 
essential for oncogenic transformation of cells by v-src (Bromberg et al., 1998b; Cao et 
al., 1996; Turkson et al., 1998). Furthermore, inhibiting Stat3 signaling leads to 
suppression of the transformed phenotype, growth arrest and apoptosis of non-small lung 
cancer cells, melanoma cells, breast carcinoma cells, head and neck cancer cells, prostate 
cancer cells, ovarian cancer cells, glioblastoma multiforme cells and melanoma B16 
tumors (Burke et al., 2001; Catlett-Falcone et al., 1999; Garcia et al., 2001; Grandis et al., 
2000; Leong et al., 2003; Mora et al., 2002; Ni et al., 2000; Nielsen et al., 1999; Niu et 
al., 2002a; Niu et al., 1999; Rahaman et al., 2002; Song et al., 2003). Further evidence for 
Stat3 mediated transformation arises from experiments with a Stat3 molecule (Stat3-C) 
that dimerizes spontaneously due to substitution of two cysteine residues within the C-
terminal loop of the SH2 domain, binds to DNA and activates transcription 
Overexpression of this construct in immortalized fibroblasts lead to transformation and 
tumor formation in nude mice (Bromberg et al., 1999).  
Taken together, these experiments suggest that Stat3 activation prevents apoptosis, 
stimulates proliferation and is involved in malignant transformation. However there are 
also examples were Stat3 activation has pro-apoptotic and growth inhibitory functions. 
Thus, as discussed earlier, Stat3 activation is an important step in IL-6 induced growth 
arrest of M1 leukemia cells (Minami et al., 1996; Nakajima et al., 1996). Additional, 
overexpression of Stat3DN reduces inhibition of cell proliferation in T47D breast cancer 
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 and A375 melanoma cells, stimulated with IL-6 and OSM (Badache and Hynes, 2001; 
Kortylewski et al., 1999), blocks LIF induced growth arrest in medullary thyroid cancer 
(MTC) cells (Park et al., 2003) and IL-6 induced growth inhibition in LNCaP prostate 
cancer cells (Spiotto and Chung, 2000). IL-10 inhibits proliferation of a mouse 
macrophage cell line (J774) and expression of Stat3DN blocks this inhibition. 
Furthermore, expression of an inducibly active Stat3-gyraseB chimera (Stat3-GyrB) is 
able to induce growth inhibition without IL-10 stimulation (O'Farrell et al., 1998). Recent 
results show a correlation with Stat3 activity and better survival. For example, node-
negative breast cancer patients with positive Phospho-Stat3 nuclear expression have a 
significantly improved survival at both short- (5-year) and long-term (20-year) (Dolled-
Filhart et al., 2003). Similarly nasopharyngeal carcinoma (NPC) patients with 
constitutive Stat5 activation, or activation of both Stat3 and Stat5, had better disease-free 
survival and overall survival, following radiotherapy, than those without activated STATs 
(Hsiao et al., 2003).  
Stat3 target genes 
The answer as to why activated Stat3 has different functions in different cell types is not 
known but it is suggested that this is due to the expression of different Stat3 target genes. 
Genes that are regulated by Stat3 are very important since they trigger signaling cascades 
that lead to the final observed biological effects (Table 11).  
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Stat3 target genes, 
upregulated by Stat3 
Cells Reference 
angiotensinogen II HepG2  (Sherman and Brasier, 
2001) 
Bcl-xl Stat3C transformed NIH3T3, 
U266 myeloma cells, head and 
neck squamous cell carcinomas 
(Bromberg et al., 1999; 
Catlett-Falcone et al., 
1999; Grandis et al., 
2000) 
cdc25A BAF/B03 pro-B cells (Fukada et al., 1998) 
C/EBP δ MCF-7  (Zhang et al., 2003a) 
c-myc Stat3C transformed NIH3T3, 
BAF/B03, murine pro-B cells, 
MCF-7, HepG2  
(Bowman et al., 2001; 
Bromberg et al., 1999; 
Kiuchi et al., 1999; 
Zhang et al., 2003a) 
cyclin A BAF/B03 pro-B cells (Fukada et al., 1998) 
cyclin D1 Stat3C transformed NIH3T3, 
MCF-7, v-src transformed 
NIH3T3 and BALB/c 3T3 
(Bromberg et al., 1999; 
Sinibaldi et al., 2000; 
Zhang et al., 2003a) 
cyclin D2 BAF/B03 pro-B cell (Fukada et al., 1998) 
cyclin D3 BAF/B03 pro-B cells (Fukada et al., 1998) 
cyclin E v-src transformed NIH3T3 and 
BALB/c 3T3 
(Sinibaldi et al., 2000) 
fibronectin MCF-7, T47D (Zhang et al., 2003a) 
mcl-1 Large granular lymphocyte 
(LGL) leukemia cells 
(Epling-Burnette et al., 
2001) 
p21 v-src transformed NIH3T3 and 
BALB/c 3T3 
(Sinibaldi et al., 2000) 
p27 A375  (Kortylewski et al., 
2001) 
p53 MCF-7 (Zhang et al., 2003a) 
pim-1 and pim-2 BAF/B03 pro-B cell (Shirogane et al., 1999) 
VEGF NIH3T3, B16 tumor cells, 
human pancreatic cancer cell 
lines 
(Niu et al., 2002b; Wei 
et al., 2003) 
Stat3 target genes, 
downregulated by 
Stat3 
Cells Reference 
cyclin D1 fetal hepatocytes  (Matsui et al., 2002) 
cyclin D2 fetal hepatocytes  (Matsui et al., 2002) 
p21 BAF/B03 pro-B cells (Fukada et al., 1998) 
p27  BAF/B03 pro-B cells (Fukada et al., 1998) 
Table 11: Stat3 target genes 
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 Stat3 could induced effects on malignant transformation; through the upregulation of 
antiapoptotic genes such as Bcl-xl, and Pim, the upregulation of genes that are important 
for cell cycle transition, for example, cyclin D1 and c-myc and the activation of 
roangiogenic factors, such as VEGF (Fig.17).  
 
Pim, mcl-1, 
Bcl-Xl 
Anti-
apoptosis 
cyclinsD1, 
D2, D3, A, 
c25, c-mycd c
G1 to S cell 
cycle 
progression 
VEGF 
Angiogenesis 
Stat3 
Fig. 17: Stat3 regulated genes important for cancer progression 
With the exception of p27 and C/EBPδ, which are upregulated by Stat3, targets that are 
involved in Stat3 mediated growth inhibition in cancer cells have not been identified yet. 
Interestingly, p27 is downregulated by Stat3 in BAF/B03 pro-B cells (Kortylewski et al., 
2001). This discrepancy might be due to the different genetic background of the cells. 
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 The transcription factor TEL 
 
TEL, a member of the E-Twenty-Six (ETS) family of transcription factors is one of the 
few ETS genes associated with human malignancies and with transcriptional repression. 
TEL is ubiquitously expressed (Poirel et al., 1997) and is essential during embryonic 
development: TEL knockout leads to embryonic lethality at day E10.5–11.5 due to severe 
defects in the developing vascular network of the yolk sac (Wang et al., 1997). Through 
alternative translation initiation at two successive AUG initiation codons in the TEL 
mRNA two nuclear proteins of 452 (TEL-M1) and 409 (TEL M43) amino-acids residues 
are encoded, TEL-M1 being the most abundantly expressed (Poirel et al., 1997). TEL 
contains several functional domains: the N-terminal pointed (PNT) homodimerization 
domain (also called B-domain, helix-loop-helix or SAM domain), which mediates 
dimerization and protein-protein interaction (Kwiatkowski et al., 1998), and an ETS 
DNA-binding domain in the C-terminus. The ETS domain is also important for protein-
protein interactions in addition to directing protein-DNA interactions. As mentioned 
before, TEL is a sequence specific transcriptional repressor of natural and model 
promoters and this repressive activity was shown to be mediated by several functional 
domains of TEL; the PNT domain, the ETS domain and in addition by a repression 
domain composed of amino acids 268-333 (Figure 18) (Chakrabarti and Nucifora, 1999; 
Fenrick et al., 1999; Lopez et al., 1999; Wang and Hiebert, 2001). 
 
Pointed  
domain 
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Repression 
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Figure 18: Domain structure of TEL protein. 
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 TEL mediated repression was shown to be dependent upon the recruitment of co-
repressors including mSin3A, SMRT, N-CoR, L(3)MBT and Tip 60 and is dependent on 
HDACs, since repression is inhibited by TSA, a general deacetylase inhibitor (Boccuni et 
al., 2003; Chakrabarti and Nucifora, 1999; Fenrick et al., 1999; Guidez et al., 2000; 
Nordentoft and Jorgensen, 2003; Wang and Hiebert, 2001).  
TEL was first identified through its implication in chromosomal translocations in 
leukemia and solid tumors (Rubnitz et al., 1999). Chromosomal translocations are 
initiated by double-strand DNA breaks, the main repair mechanism underlying the 
resultant illegitimate recombination is probably non-homologous end-joining. The 
products of chromosomal translocations are fusion genes, generated by fusion of TEL to 
unrelated genes leading to the expression of oncogenes with either altered transcriptional 
regulation or constitutive kinase activity. The N-terminal PNT of TEL is usually fused to 
tyrosine kinases including platelet-derived growth factor β (PDGFRβ), c-ABL, and JAK2 
(Golub et al., 1994; Golub et al., 1996; Hiebert et al., 1996; Lacronique et al., 1997). 
However, the most prominent chromosomal translocation fuses the PNT of TEL to the 
acute myeloid leukemia (AML) transcription factor (Golub et al., 1995; Romana et al., 
1995). Interestingly, the second allele of TEL was deleted in some of the described cases  
above, suggesting that TEL is a tumor suppressor (Stegmaier et al., 1995). Further 
evidence for the role of TEL as tumor suppressor is supported by three studies; first, 
overexpression of TEL, in Ras-transformed NIH3T3 cells, inhibits cell growth and tumor 
formation in nude mice (Rompaey et al., 2000) second, TEL represses the expression of 
stromelysin-1, a metalloproteinase that is important in tissue remodeling and tumor cell 
invasion (Fenrick et al., 2000), third, mutational inactivation of TEL might occur in 
prostate carcinoma and ovarian cancer (Hatta et al., 1997; Kibel et al., 2002). Not much is 
known about the regulation of TEL. However, some evidence indicates that TEL is 
regulated at translational and post-translational levels. So far two types of post-
translational modifications have been identified, phosphorylation and sumoylation. Both 
isoforms of TEL are subject to phosphorylation events, although, the function of 
phosphorylation is still unknown (Poirel et al., 1997). Sumoylation of TEL at lysine 99, 
within the PNT domain, by the ubiquitin-conjugating enzyme (UBC9) leads to nuclear 
export of TEL and therefore regulates TEL’s repressive ability (Wood et al., 2003). 
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 SUMMARY 
 
The Stat3 transcription factor is required for the anti-proliferative effects induced 
by cytokines, such as interleukin-6-type cytokines. In order to investigate the role of 
Stat3 in inhibition of cell proliferation, we have used an inducible Stat3 construct in 
A375 melanoma cells. We found that activation of Stat3 to moderate levels was sufficient 
to repress A375 proliferation, by slowing cell transit through the cell cycle. Enhanced and 
prolonged Stat3 activity led to cell cycle arrest and apoptosis. Genes whose expression 
was altered by Stat3 activation were identified by oligonucleotide microarray analysis. 
One of the Stat3 targets, C/EBPδ, is involved in Stat3 anti-proliferative activity, as 
revealed by small interfering (si) RNA targeting. Interestingly, TEL (ETV6), a novel 
Stat3 target identified in this study, is a negative regulator of Stat3 activity. SiRNA-
mediated inhibition of TEL expression resulted in increased Stat3-dependent 
transcriptional activity and stronger Stat3 anti-proliferative activity. Confirming these 
results, overexpression of TEL repressed Stat3 transcriptional activity; intriguingly, this 
effect did not require the TEL DNA-binding domain. Inhibition of Stat3 activity by TEL 
represents a novel mechanism regulating the Stat3 signaling pathway. 
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 Introduction 
Signal transducer and activator of transcription 3 (Stat3)1 is a latent cytoplasmic 
transcription factor that can be activated by a variety of kinases, including receptor 
tyrosine kinases and cytoplasmic kinases associated with cytokine receptors. Stat3 
appears to play a critical role in the control of many biological processes during 
development (1-3) and is associated with cell proliferation, differentiation and survival 
(4). However, constitutive activation of Stat3 has been associated with oncogenesis. 
Indeed, there is increasing evidence that Stat3 is activated in a wide variety of human 
tumors, including head and neck, prostate and breast carcinomas, multiple myelomas and 
lymphomas (5,6). Moreover, experimental studies revealed that Stat3 is required for 
transformation by oncogenic tyrosine kinases such as v-Src, TEL-ABL and TEL-JAK (7-
9), and that activation of Stat3 is sufficient for transformation of fibroblasts and Ba/F3 
cells (9,10). On the other hand, members of the interleukin (IL)-6 family of cytokines 
which include IL-6, oncostatin M (OSM), leukemia inhibitory factor, and ciliary 
neurothrophic factor have been shown to inhibit proliferation of some leukemia, 
melanoma, prostate and breast cancer cells (11-14). Inhibition of cell proliferation by 
IL6-type cytokines was shown to be mediated by Stat3 (15-17). Moreover, recent 
observations indicate that, active, nuclear Stat3 correlates with a better prognosis in node-
negative breast tumors and nasopharyngeal tumors (18,19). These results indicate that 
Stat3 contributes to anti-proliferative, and maybe anti-oncogenic effects, in some cellular 
contexts. 
  Binding of IL-6-type cytokines to their receptors leads to hetero-oligomerization 
with the common signal transducer gp130, resulting in activation of the receptor 
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 associated Janus kinases (JAKs) and phosphorylation of specific tyrosine residues in the 
cytoplasmic tail of gp130. The phosphorylated tyrosines serve as docking sites for two 
major signal-transducing molecules: SHP2 (Src homology domain 2 protein tyrosine 
phosphatase) which interacts with adaptor molecules such as Gab1/2, p85 and Grb2 
leading to activation of the mitogen-activated protein kinase (MAPK) and the 
phosphatidylinositol 3-kinase (PI3K) intracellular signaling pathways (20); and Stat3, 
which will in turn be phosphorylated by the JAKs (21). Tyrosine phosphorylation allows 
Stat3 dimerization, translocation to the nucleus, binding to specific DNA sequences and 
activation of transcription (10,22). Considering the critical role of Stat3 in controlling cell 
growth and differentiation, it is not surprising that negative regulators of Stat3 that 
control Stat3 activity at multiple levels, have been identified (22): e.g. control of JAK 
activity by SOCS (23), dephosphorylation of Stat3 by nuclear phosphatases (24), 
regulation of Stat3 nuclear translocation by GRIM-19 (25) and prevention of DNA 
binding by PIAS3 (26) . 
 We have further investigated the mechanism underlying Stat3 anti-proliferative 
effects. Using a conditionally active Stat3 construct, we found that activation of Stat3 
was sufficient to inhibit A375 melanoma cell proliferation. Transcriptional targets of 
Stat3 in A375 cells were determined by oligonucleotide microarray analysis. We found 
that the leucine zipper transcription factor C/EBPδ, one of the targets identified in our 
screen, is a mediator of Stat3-induced inhibition of melanoma cell proliferation. 
Moreover, we identified Tel/ETV6, a member of the ETS family of transcription factors, 
as a Stat3 target and, interestingly, discovered that TEL is a novel repressor of Stat3 
transcriptional and biological activity. 
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 MATERIALS AND METHODS 
 
Reagents and plasmids-Recombinant human IL-6 and OSM were from 
PeproTechEC (London, UK). 4-hydroxytamoxifen (4HT) was from Sigma (St. Louis, 
MO). Human erythropoietin (EPO) was from R&D Systems (Minneapolis, MN). The 
plasmid containing the mutated ligand-binding domain of the murine estrogen receptor 
(ERTM) was kindly provided by T. Littlewood (Imperial Cancer Research Fund, London, 
UK). ERTM was cloned into pcDNA3.1 as a BamH1-EcoR1 fragment. The Stat3 
sequence with an additional BamH1 site was obtained by PCR amplification from 
pRc/CMVStat3 (kindly provided by J. E. Bromberg and J. F. Darnell, Rockefeller 
University, NY, NY) and cloned into pcDNA3.1-ERTM. The chimeric receptors 
consisting of the extracellular part of the murine EPO receptor fused to various regions of 
gp130 cytoplasmic domain (16) were a kind gift from M. Kortylewski and I. Behrmann 
(RWTH, Aachen, Germany). The pCMV-TEL, pCMV-TEL∆P, pCMV-TEL∆122-176, 
pCMV-TEL∆122-217, pCMV-TEL∆268-333 and pCMV-TEL∆303-333 constructs, 
generously provided by S. W. Hiebert (Vanderbilt University School of Medicine, 
Nashville, TN), were previously described (27). TEL DBDM construct (28), kindly 
provided by G. Grosveld  (St. Jude Children’s Research Hospital, Memphis, TN), was 
subcloned into pCMV.  
Cell Culture and cell transfection-A375 melanoma cells were maintained in 
RPMI supplemented with 5% fetal calf serum (FCS; Invitrogen, Inc., Grand Island, NY). 
HEK293T cells were maintained in DMEM supplemented with 10% FCS (Invitrogen). 
For transient expression, plasmids were introduced into cells using the Effectene reagent 
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 (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Stable ASER cells 
were obtained by transfection of A375 cells with pcDNA3.1-Stat-ER. Transfected cells 
were selected using 1 mg/ml G418 (Invitrogen) and several clones were picked, expanded 
and analyzed for STAT3-ER expression. Similar results were obtained with two 
independent clones. 
For siRNA transfection, cells were plated at a density of 5 x 104 cells/well in six-
well dishes, 24 h before transfection. The RNA oligonucleotides were obtained from 
XERAGON Inc. (Huntsville, AL). SiRNA duplexes (0.2 nmole/well) were introduced 
into the cells using 3 µl OligofectAMINE reagent (Invitrogen) according to the 
manufacturer’s protocol. The following 21-mer oligoribonucleotide pairs were used: for 
C/EBPδ (accession number NM005195) nucleotide 844 to 864, for TEL (accession 
number NM001987) nucleotide 540 to 560, for control LacZ (accession number M55068) 
nucleotide 4277 to 4297 (obtained from D. Cappellen, FMI, Basel). SiRNA sequences 
were ‘blasted’ against the GenBank®/EMBL databank to ensure gene specificity. 
Transfection with expression vectors was carried out using Effectene 24h after 
introduction of siRNA. 
Immunoprecipitation and western blots-Cells were harvested and lysed in NP40 
extraction buffer [50 mM Tris (pH 7.5), 1 mM EGTA, 5 mM EDTA, 120 mM NaCl, 1% 
NP40, 2 mM sodium orthovanadate, 50 mM sodium fluoride, 20 mM ß-
glycerophosphate, 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 0.5 mM 
phenylmethylsulfonyl fluoride] for 5 min on ice. The lysates were clarified by 
centrifugation and protein concentration was determined using the Bio-Rad protein assay 
reagent (Bio-Rad Laboratories GmbH, Munich, Germany). For immunoprecipitation, 
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 equal amounts of proteins were incubated with an anti-Stat3 antibody (F-2; Santa Cruz 
Biotechnology, Santa Cruz, CA) for 1 h. Immune complexes were collected with protein 
G-Sepharose (Sigma) and washed three times with lysis buffer. Precipitated proteins were 
released by boiling in loading buffer and subjected to SDS-PAGE. Proteins were 
transferred onto polyvinylidene difluoride membranes (Boehringer Mannheim, 
Mannheim, Germany). After blocking with 10 % horse serum (Invitrogen) in 50 mM Tris 
pH 7.5, 150 mM NaCl, 0.05 % Tween20, filters were probed with specific antibodies: c-
Tel (kindly provided by G. Grosveld), Stat3 (C-20), cyclin D2, cyclin D3 and cyclin E 
from Santa Cruz Biotechnology, phospho-Stat3 (Tyr 705) and p27 Kip1 from Cell 
Signaling Technology (Beverly, MA), cyclin D1 from Novocastra Laboratories Ltd, 
Newcastle upon Tyne, UK. Proteins were visualized with peroxidase-coupled secondary 
antibodies using the enhanced chemiluminescence detection system (Amersham 
Pharmacia Biotech, Little Chalfont, UK). 
DNA-binding assay-Nuclear extracts from cells treated with 4HT (1 µM) or OSM 
(100 ng/ml) were prepared as described (29). To measure ETS DNA binding, nuclear 
extracts were pre-cleared with immobilized NeutrAvidin beads (Pierce, Rockford, IL). 
5’-biotinylated double-stranded oligonucleotide, corresponding to the ETS-binding 
sequence 5’-ATAAACAGGAAGTGG-3’ (30), was pre-incubated with NeutrAvidin 
beads. Immobilized ETS oligonucleotides or Stat3 TransCruz oligonucleotide agarose 
conjugate (Santa Cruz Biotechnology) were added to 80 µg of nuclear extracts in binding 
buffer (20 mM HEPES, 0.5 mM EDTA, 1 mM DTT, 2 µg/ml poly dI-dC) and rotated for 
2 h at 4°C. Samples were centrifuged and the pellets were washed three more times with 
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 binding buffer. Proteins were eluted from beads by boiling in loading buffer and SDS-
PAGE was performed as described above. 
   Flow Cytometric Analyses-Cells were harvested after treatment with 4HT or 
OSM/4HT, washed three times with ice-cold phosphate-buffered-saline (PBS) and 
resuspended in propidium iodide buffer [1mM sodium citrate (pH 4.0), 1.5 mM NaCl, 5 
mM EDTA, 5 mM EGTA, 0.1 % NP40, 4 mg/ml propidium iodide and 80 mg/ml 
RNaseA]. After 30 min incubation on ice, cell cycle distribution was measured with a 
Becton Dickinson FACScan flow cytometer. In some cases, the cells were arrested in the 
G1 phase of the cell cycle, by treating cultures with UO126 (25 µM; Promega 
Corporation, Madison, WI) for 24 h either with or without the addition of 4HT. Cells 
were then washed in PBS before addition of control or 4HT-containing medium. Cells 
were harvested at the times indicated in Fig. 3B and treated as described above.  
Luciferase Assays-Cells (2 x 105 cells in 6-well plates) were transfected, as 
described above, with a luciferase reporter containing four copies of the acute phase 
response element (APRE) from the α2-macroglobulin gene in front of the minimal junB 
promoter (14), a generous gift from Dr M. Hibi and T. Hirano (Osaka University, Osaka, 
Japan), together with the Renilla control plasmid pRL-SV40 from Promega. Twenty-four 
hours after transfection, cells were either left unstimulated or stimulated with OSM, 4HT 
or the combination of 4HT/OSM for 24 hours. In some instances, Trichostatin A (Sigma) 
was added to the medium at 250 nM. The preparation of cell extracts and measurement of 
luciferase activity were carried out using the Dual-Luciferase reporter assay system (from 
Promega) in an Autolumat LB953 (Berthold Technologies, Wildbad, Germany). Changes 
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 in firefly luciferase activity were expressed relative to Renilla luciferase activity in the 
same sample. 
Microarray analysis and quantitative radioactive RT-PCR-Microarray analysis 
was performed using HG U95A GeneChips™ (Affymetrix, Santa Clara, USA). Biotin-
labeled cRNA probes were generated from each sample starting from 10 µg of total 
cellular RNA, which was extracted using TRIzol (Invitrogen) and further purified with 
the RNeasy mini kit (Qiagen) according to the manufacturer's instructions. The cRNA 
probes were hybridized on the arrays and signals detected according to the 
manufacturer’s instructions. Chip analysis was performed using the Affymetrix 
Microarray Suitev5 (target intensity 500 used for chip scaling) and GeneSpring 4.2.1 
(Silicon Genetics). Changes in gene expression were assessed by looking for concordant 
changes between replicates using a signed Wilcoxon rank test (as recommended by 
Affymetrix). The “change” p-value threshold was < 0.003 for increase and > 0.997 for 
decrease. After concordance analysis these values become < 9 x10-6 and > 0.999991 
respectively. Any gene whose detection p-value was > 0.05 was discarded from the 
analysis. 
For quantitative PCR, cells were transfected with siRNA duplexes 48 h before 
treatment with 4HT. Cells were then harvested in a guanidinium isothiocyanate-
containing buffer and total RNA was purified using RNeasy mini kit (Qiagen). The 
quantitative radioactive RT-PCR for C/EBPδ was performed as described (31) using the 
following primers: forward 5’-GCCGACCTCTTCAACAGCAA-3’ and reverse 5’-
CAAGCTCACCACGGTCTGTC-3’ (30 cycles).  
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 RESULTS 
 
 Stat3-ER is a tool to investigate biological functions of Stat3. 
 Stat3 is required for inhibition of breast carcinoma and melanoma cell 
proliferation by IL-6-type cytokines. In order to investigate the role of Stat3 in this 
process, independently of other IL-6-induced signaling pathways, we designed a 
conditionally active Stat3. It has been shown that dimerization of Stats is sufficient for 
nuclear translocation, even in the absence of Tyr phosphorylation (10,32). Therefore, the 
entire Stat3 coding sequence was fused to the estrogen receptor ligand-binding domain 
(ER-LBD), which contains a dimerization domain. In the presence of the ER-LBD ligand 
4-hydroxytamoxifen (4HT), similar chimeric constructs were shown to translocate to the 
nucleus and stimulate Stat-dependent transcription (32). 
  The Stat3ER construct was transfected into A375 melanoma cells, whose 
proliferation has been shown to be reduced by IL-6 and OSM (16), and A375 clones 
expressing high levels of Stat3-ER (ASER clones) were selected. Using a consensus 
Stat3-binding oligonucleotide as an affinity probe, Stat3-ER DNA binding activity was 
measured in nuclear extracts obtained from ASER cells, treated with 4HT for different 
times (Fig. 1A). While low Stat3ER-DNA binding, as measured by western blotting 
analysis of the oligonucleotide-bound proteins, was detected as early as 20 min after 
stimulation, binding increased strongly after two hours to reach a maximum 24 h after 
4HT addition (Fig. 1A). This increase in DNA binding was accompanied by an increase 
in Stat3-ER protein levels, probably due to ligand-dependent stabilization of the Stat3-ER 
fusion protein (data not shown).  
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 Transcriptional activity of Stat3-ER in ASER cells was verified by introduction of 
a luciferase reporter gene driven by the acute-phase response element (APRE) of the α2-
macroglobulin gene, a Stat3 target. 1 µM 4HT, which we have determined to be the 
optimal concentration, stimulated APRE reporter activity as efficiently as 100 ng/ml 
OSM (Fig.1B). Thus, Stat3-ER appears to be an appropriate tool to study the mechanism 
underlying Stat3’s biological activity.  
In order to evaluate the role of Stat3 in A375 cell proliferation, ASER cells were 
grown for 3 days in the presence of 4HT or OSM. Treatment with 1 µM 4HT reduced 
ASER cell number by about 40 %, which is equivalent to the effect of 100 ng/ml OSM 
(Fig. 1C).  4HT, at 1 µM, does not affect proliferation of A375 cells (data not shown), 
confirming that the anti-proliferative effects of 4HT are due to Stat3-ER activation. Thus, 
while Stat3 was previously shown to be required for OSM-induced inhibition of cell 
proliferation (15,16), our results show that it is also sufficient for this effect. 
Interestingly, the combination of 4HT and OSM had a dramatic effect on proliferation, 
reducing cell number by more than 90% over the 3-day time course (Fig. 1C). This 
observation raised the possibility that other pathways induced by OSM might reinforce 
Stat3’s biological activity. 
 OSM enhances Stat3-ER transcriptional activity and DNA binding. 
The mechanism by which 4HT and OSM cooperate to repress cell proliferation 
was further investigated. With respect to the APRE-driven reporter assay, the 
combination of 4HT and OSM dramatically increased luciferase activity, compared to the 
activity induced by 4HT or OSM alone (Fig. 1B). For instance, transcription induced by 
combination of 1 µM 4HT with 100 ng/ml OSM was more than 100-fold stronger than 
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 the transcriptional activity induced by the single agents. IL-6 showed the same 
cooperative effect with 4HT (data not shown). Thus, in ASER cells, 4HT and gp130 
signaling synergize to increase Stat3 transcriptional activity. 
In A375 cells, OSM and IL-6 binding to their receptors trigger multiple signaling 
pathways including the JAK/Stat, the MAPK and PI3K pathways (data not shown). We 
have investigated whether these pathways are responsible for enhancing Stat3-ER 
transcriptional activity, by using chimeric receptors composed of the extracellular domain 
of the erythropoietin (EPO) receptor fused to various regions of the gp130 cytoplasmic 
domain (Fig. 2A), in order to specifically activate individual pathways (33). EPO was 
used to activate chimeric gp130 signaling, but not endogenous gp130 (34). A375 cells 
were transfected with the EG chimera, which contains the transmembrane and the entire 
cytoplasmic domain of gp130 (Fig. 2A), together with the Stat3-ER construct and the 
APRE-driven luciferase reporter. Stat3 transcriptional activity was evaluated after 
treatment with EPO and/or 4HT. While EPO and 4HT added individually had only a 
modest effect on Stat3 activity, the combined addition of EPO and 4HT induced strong 
luciferase activity in EG expressing cells (Fig. 2B). A chimera containing only the 
membrane-proximal box1/box2 region of gp130, which mediates association with the 
JAKs, but has none of the Tyr residues required for Stat3 or SHP2 recruitment (∆B; Fig. 
2A), failed to respond to the concomitant addition of 4HT and EPO in comparison to 
4HT alone. These results show that the chimeric receptors are an appropriate tool for 
studying the synergistic effect between the 4HT and gp130 signals. Cells were also 
transfected with chimeric receptor constructs containing the Stat3 (Y814) or SHP2 
(Y759) tyrosine modules attached to the ∆B receptor, resulting in receptors capable of 
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 specifically activating Stat3 or the MAPK/PI3K pathways, respectively (35). Treatment 
of the Y814-transfected cells with EPO and 4HT strongly increased transcriptional 
activity when compared to the response observed when the ligands were added 
individually (Fig.2B). In contrast, in cells expressing the receptor with the SHP2 module 
(Y759), no synergy was observed between EPO and 4HT (Fig. 2B). These results 
indicate that the gp130/4HT synergy involves only Stat3 signaling and not the SHP2-
dependent pathways. 
Next, we examined specific DNA binding of Stat3-ER to a Stat3 consensus 
oligonucleotide. ASER cells were treated with 4HT to induce Stat3-ER binding. OSM 
was then added for the indicated times and DNA binding of Stat3-ER and endogenous 
Stat3 was monitored as described above. Binding of endogenous Stat3 to the DNA probe 
could be detected 15 min after addition of OSM, peaked at 30 min and  returned to low 
levels after 1 h of treatment (Fig. 2C, upper panel). In the presence of OSM, Stat3-ER 
DNA binding was enhanced and, unlike the endogenous Stat3, was maintained for 
several hours (Fig 2C, upper panel). Levels of Tyr705 phosphorylation of Stat3/Sta3-ER 
followed the kinetics of DNA binding (Fig. 2C, lower panel). These results indicate that 
OSM-induced gp130 activation leads to phosphorylation of both Stat3 and Stat3-ER; 
while Stat3 gets rapidly dephosphorylated, Stat3-ER displays prolonged phosphorylation 
and DNA-binding. This result could explain the synergy between 4HT and OSM for 
Stat3-dependent transcriptional activity and Stat3-induced inhibition of cell proliferation. 
 Stat3 activity inhibits A375 cell proliferation. 
 In order to understand the mechanism by which Stat3 activity leads to decreased 
cell number, cell cycle analyses were performed after treatment of ASER cells with 4HT 
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 and/or OSM for up to 3 days. Flow cytometry revealed that neither 4HT (Fig. 3A) nor the 
physiological activator OSM (data not shown) significantly affected the cell cycle profile, 
i.e., there was no obvious accumulation of cells in a particular phase of the cell cycle. 
A375 cells can be arrested in the G1 phase of the cell cycle by blocking the Ras/MAPK 
pathway (35). ASER cells that had first been synchronized in the G1 phase of the cell 
cycle and then released in 4HT-containing medium showed delayed entry into the S 
phase compared to cells released in control medium (Fig. 3B). These results suggest that 
Stat3 activity negatively influences proliferation by increasing transit time of the cells 
through the cell cycle, without influencing a particular phase of the cell cycle.  
In contrast to treatment with a single compound, ASER cells treated for 24 hrs 
with a combination of 4HT and OSM accumulated in the G1 phase of the cell cycle (+ 
24%; Fig. 3C). After 3 days, a large proportion of these cells underwent apoptosis, as 
indicated by the appearance of a sub-G1 peak and PARP cleavage (not shown). Thus, the 
striking reduction in cell number induced by the combined action of 4HT and OSM is 
largely due to cell death. 
We next analyzed nuclear cell cycle regulators known to be involved in the G1-S 
transition. There were no detectable changes in the protein levels of cyclin D1, D2 or D3, 
or the cyclin-dependent kinase inhibitor p27Kip1, in cells treated with 4HT or OSM for 24 
h (Fig 3D); p21Cip1 was not detected in any of the ASER lysates (data not shown). In 
contrast, cells treated with the combination of 4HT and OSM had lower amounts of 
cyclin D2, increased expression of p27Kip1 (Fig. 3D) and increased levels of cdk2/p27Kip1 
complexes (data not shown), which is the likely cause of the accumulation of cells in G1 
(Fig. 3C).   
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  Transcriptional profiling of Stat3 target genes. 
We used oligonucleotide microarrays to identify Stat3 target genes that might 
contribute to the anti-proliferative effects of Stat3. Experiments were carried out on two 
independent ASER clones expressing similar amounts of Stat3-ER and showing a similar 
response to 4HT with respect to DNA binding, reporter gene assays and inhibition of cell 
proliferation (data not shown). Stat3 DNA binding (Fig. 1A) and reporter gene activity 
(data not shown) were strongly increased after 2 to 4 h of 4HT treatment. Accordingly, 
RNA was collected from Stat3-ER expressing cells after 4 and 24 h of 4HT treatment. 
RNAs from three independent experiments were pooled and the resulting biotinylated 
cRNAs were hybridized to the Affymetrix U95A oligonucleotide array containing probe 
sets for over 12,000 transcripts. Genes that were significantly increased or decreased in 
both clones, relative to untreated cells (change p<0.00009) were identified. Genes that 
were significantly increased or decreased upon 4HT treatment of parental, non-
transfected A375 cells were excluded from the study.  
Several known direct targets of Stat3 were induced upon 4HT treatment of ASER 
cells, validating the experimental approach. For example, 4 h after addition of 4HT, the 
JAK inhibitor SOCS3, α-antichymotrypsin (serpin A3) and the transcription factors 
C/EBPδ and JunB were significantly increased (data not shown). Some genes, not 
previously described as Stat3 targets, were also activated within 4 h; these include the 
transcription factor TEL (ETV6), the death-associated protein kinase 1 (DAPK1) and the 
serine protease inhibitor serpin B3.  
After 24 h, 4HT-induced Stat3 activation resulted in altered expression of a 
number of genes; 154 genes were increased and 23 were decreased. Genes whose 
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 expression was increased more than 1.5 fold (64 genes) or decreased more than 1.3 fold 
(11 genes) are listed (Fig. 4). These genes belong to various functional groups encoding: 
transcriptional regulators that could mediate the Stat3 effect (TEL, C/EBPδ, FOS); 
receptors, e.g. OSM receptor; intracellular signaling molecules; adhesion proteins such as 
osteopontin (secreted phosphoprotein 1) and genes involved in various aspects of cellular 
metabolism.  
Most of these genes were also activated by OSM, however, to a lower extent, 
most likely because OSM triggered a more moderate transcriptional response. It is 
noteworthy that the majority of these genes is sensitive to the level of Stat3 activity, as 
they are very highly induced by the combined 4HT/OSM treatment (Fig. 4). However, 
4HT/OSM triggered the activation of many more genes, which were not induced by 4HT 
alone (data not shown), which might be involved in specific program leading to G1 arrest 
and cell death. 
The function of some Stat3 target genes (induced by 4HT treatment and by OSM 
treatment) identified in this screen was investigated further. We focused on two 
transcription factors whose expression is increased at early time points, since each of 
these could in turn control expression of secondary target genes contributing to Stat3’s 
biological effects. C/EBPδ, a previously described Stat3 target, has been implicated in 
growth arrest of mammary epithelial cells (36). TEL, a newly identified Stat3 target, 
which belongs to the ETS family of transcription factors, is known to repress 
transcription of some genes that have an ETS consensus site in their promoter (37).  
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  C/EBPδ mediates the anti-proliferative effect of Stat3. 
The contribution of C/EBPδ to the anti-proliferative activity of Stat3 was 
evaluated using siRNA to knock-down its expression. When examined by quantitative 
PCR, C/EBPδ mRNA was increased following 4HT treatment (Fig 5A), confirming the 
data obtained by microarray analysis. Specific siRNA significantly reduced the 
expression of C/EBPδ, both basal and in response to 4HT (Fig. 5A, right lanes). The 
knock-down of C/EBPδ expression decreased Stat3’s anti-proliferative activity in ASER 
cells by ~ 40 % (Fig. 5B; average of three independent experiments). Thus, C/EBPδ plays 
an important role in the anti-proliferative effects of Stat3.  
 TEL is a negative regulator of Stat3 activity. 
The role of the newly identified Stat3 target, TEL, in Stat3’s anti-proliferative 
effect was further evaluated. Microarray data indicate that TEL mRNA is increased 
within 4 h of Stat3 activation. Two TEL protein isoforms are found in most cells 
corresponding to initiation of TEL mRNA translation at ATG codon 1 and 43. Protein 
levels of both isoforms, TEL and TEL-43, steadily increased from 8 h after addition of 
4HT to ASER cells (Fig. 6A). We also examined a panel of cancer cell lines and 
determined TEL levels in response to IL-6-type cytokines. TEL protein levels were 
significantly increased after IL-6 or OSM treatment of T47D and SKBr-3 breast 
carcinoma cells, DU145 prostate carcinoma cells and HepG2 hepatoma-derived cells 
(Fig. 6B), suggesting that TEL is a fairly common Stat3 target. However, TEL protein 
level was unchanged in other cell lines, especially those with constitutively elevated TEL 
levels, such as LNCaP prostate carcinoma and MDA-MB-468 breast carcinoma cells.  
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 The role of TEL in Stat3 signaling was explored by knocking down its expression. 
Transfection of TEL siRNA strongly reduced TEL expression relative to the levels 
observed in cells transfected with the control LacZ siRNA (Fig. 7A). In contrast to the 
results observed after C/EBPδ knock-down, in the presence of TEL siRNA, Stat3-
mediated inhibition of ASER cell proliferation was stronger (Fig. 7B), suggesting that 
TEL might be a Stat3-induced negative regulator of Stat3 signaling.  
Since TEL is a transcriptional repressor (38), we tested whether siRNA-mediated 
knock-down of TEL affected Stat3 transcriptional activity. Stat3-dependent transcription 
induced by 4HT or OSM was significantly increased when TEL expression was reduced 
(Fig. 7C). Conversely, overexpression of TEL in ASER cells (Fig. 8A) and in HEK-293T 
cells (Fig. 8C) resulted in decreased Stat3 activity induced by 4HT and OSM, 
respectively. These results demonstrate that TEL is a negative regulator of Stat3 
transcriptional activity.  
 Mechanism of TEL-dependent repression of Stat3 activity. 
Our results show that TEL is a repressor of Stat3 transcriptional activity. A 
number of negative regulators acting at different levels of the Stat3 signaling cascade 
have been identified. The SOCS proteins inhibit JAK activity leading to decreased Stat3 
Tyr phosphorylation; GRIM-19 interferes with Stat3 nuclear shuttling and PIAS3 
prevents Stat3 from binding to DNA (25,26,39). Overexpression of TEL in A375 cells 
did not affect the Stat3 expression levels or tyrosine phosphorylation in response to OSM 
(data not shown). Moreover, Stat3 nuclear translocation and DNA binding were not 
changed when TEL was over-expressed in A375 cells (data not shown). Thus, TEL 
functions differently from the previously identified negative regulators of Stat3.  
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 TEL repressor activity is dependent on the recruitment of a co-repressor complex, 
including molecules such as mSin3A, NcoR and SMRT (27,40). Since these three 
proteins are known to interact with histone deacetylases (HDACs), we tested the 
possibility that HDAC recruitment plays a role in TEL-dependent repression of Stat3 
activity using Trichostatin A (TSA), a general HDAC inhibitor. Addition of TSA to 4HT-
stimulated ASER cells prevented the repression of Stat3 activity by TEL (Fig. 8A), 
suggesting that TEL repressor activity toward Stat3 is dependent on the recruitment of 
HDACs. 
The co-repressor, HDAC-containing complex has been shown to interact with at 
least two different domains of TEL: the pointed domain and a central repression domain 
(27,40). To identify the domains of TEL essential for repression of Stat3 transcriptional 
activity, various TEL mutants (Fig. 8B) were overexpressed in ASER cells or HEK-293T 
cells and 4HT- or OSM-induced Stat3 transcriptional activity was evaluated (Fig. 8C and 
D). Among the TEL mutants tested, only TEL ∆P, lacking the pointed domain, failed to 
repress Stat3 activity. Mutants with deletions in the central domain were still able to 
block Stat3 activity. Thus, repression of Stat3 activity by TEL requires an intact pointed 
domain. Intriguingly, a TEL DNA-binding domain mutant (TEL DBDM) retained the 
ability to repress 4HT- or OSM-induced Stat3 activity in ASER and HEK-293T cells 
respectively (Fig. 8C and D, right panels), showing that TEL represses Stat3 activity 
independently of its DNA-binding domain.  
 We next investigated the possibility that Tel and Stat3 form a complex in the 
nucleus of A375 cells. As expected, there was an increase in nuclear Stat3 levels 
following OSM addition, while TEL levels in the nucleus were unaffected by cytokine 
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 treatment (Fig 9, right panels). TEL was detected in immunoprecipitates of Stat3, with 
increased levels in the OSM treated lysates, reflecting increased nuclear Stat3 (Fig 9, left 
panels). Pull-downs of TEL using an immobilized ETS consensus site-containing 
oligonucleotide confirmed this association, showing that there was more of the TEL/Stat3 
complex in the nuclei of OSM treated cells (Fig. 9, middle panels). Taken together, these 
results lead us to suggest that TEL represses Stat3 transcriptional activity by interacting 
with Stat3 and recruiting HDACs to the Stat3 transcriptional complex. 
 
DISCUSSION 
 
Stat3 mediates the effects of multiple growth factors and cytokines and, as such, 
Stat3 is involved in many physiological processes, but also in disease, such as cancer. 
The identification of Stat3 effectors and regulators should improve our understanding of 
the multiple and sometimes contradictory biological roles attributed to this transcription 
factor. Indeed, some studies describe a role of Stat3 in oncogenesis, while others 
demonstrate its ability, acting downstream of cytokine receptors, to inhibit tumor cell 
proliferation. We have evaluated the anti-proliferative effect of Stat3 by introducing a 
conditionally active Stat3 into A375 melanoma cells. Our results show that depending on 
the extent of Stat3 activity, the cancer cells show decreased proliferation, or growth arrest 
accompanied by apoptosis. Stat3 targets in the melanoma cells were identified using 
oligonucleotide microarray analyses. Functional studies were carried out on two 
transcription factors whose expression was rapidly induced by Stat3: C/EBPδ, a 
previously described Stat3 target; and TEL, a novel Stat3 target, which is a member of 
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 the ETS family of transcription factors. We report here that, in accordance with studies 
performed in mammary epithelial cells (41), C/EBPδ has an important role in mediating 
Stat3’s anti-proliferative effect on A375 melanoma cells. In contrast, TEL is a novel 
repressor of Stat3 activity: the overexpression of TEL leads to decreased Stat3-driven 
transcription and the loss of TEL results in stronger Stat3-dependent transcription and 
anti-proliferative effects.   
Stat3 activation  caused a general decrease in the progression of A375 cells 
through all phases of the cell cycle, without affecting the levels of the major regulators of 
the G1-S transition, including p21, p27, D-type cyclins or cyclin E. Our results are in 
contrast to previous studies showing accumulation of cells in G1 and an increase in p27 
levels upon cytokine-triggered Stat3 activation (16,42). This discrepancy might reflect 
differences in levels of Stat3 activity achieved or differences in the sensitivity of the cells 
to active Stat3. Indeed, we observed that further enhancing Stat3 activity in A375 cells, 
by combining 4HT with OSM, led to an increase in p27 levels, an accumulation of cell in 
G1 and massive apoptosis.   
While a number of previously described Stat3 target genes, e.g. JunB, serpin A3, 
fibronectin or VEGF (5,43,44) were detected in our analysis, others, including Pim 1 or 
angiotensinogen (5,45) were only detected when Stat3 activity was synergistically 
enhanced by 4HT and OSM2. However, some genes, such as Bcl-XL, cyclin D1 and Myc, 
which were strongly up-regulated by Stat3 activation in rat fibroblasts (10) were not 
increased even after combined treatment of A375 cells with 4HT and OSM. Thus, Stat3’s 
ability to affect specific target genes is dependent upon the cellular context.  
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 Considering the importance of Stat3 in different biological processes, tight 
regulation of the Stat3 signaling pathway is essential and is achieved via diverse 
mechanisms. We have identified TEL, a novel Stat3 target, and have shown that it plays a 
role in a Stat3 negative feed-back loop.  In contrast to other negative regulators of Stat3,  
e.g. SOCS3, GRIM-19 and PIAS3 (25,26,46), which act at various levels of the 
JAK/Stat3 pathway causing an overall reduction in DNA-bound Stat3, TEL does not 
affect Stat3 DNA binding, but represses its transcriptional activity. Our finding that TEL 
levels are induced in many different cancer cell lines after IL6 or OSM treatment 
suggests that TEL might be a general Stat3-induced negative regulator.   
The repressive activity of TEL has previously been shown to depend on 
recruitment of a co-repressor complex comprising mSin3A, NcoR and histone 
deacetylases (HDACs)  to distinct TEL domains (27,40,47,48): the C-terminal pointed 
domain (also called helix-loop-helix domain or B-domain), which is necessary for TEL 
oligomerization and association with other proteins (38,48,49); the N-terminal ETS 
domain, which interacts with specific DNA elements, but also mediates protein-protein 
interactions (27,49,50); and the central TEL region spanning amino-acid residues 268-
333, which has been found to associate with HDAC3 (27). We show here that TEL-
mediated repression of Stat3 is dependent on HDAC activity and found that the TEL 
pointed domain, but not the central region, is required for this repression.  
Interestingly, neither point mutations in the ETS domain, which prevent TEL 
DNA-binding, nor complete deletion of the ETS domain3 prevented repression of Stat3 
activity. To our knowledge, this is the first study showing that TEL repressor function 
does not require the ETS DNA binding domain. The fact that TEL and Stat3 could be co-
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 immunoprecipitated from nuclear extracts suggests that TEL can be recruited to the Stat3 
transcriptional complex, even in the absence of DNA-binding, through protein-protein 
interaction. 
By knocking-down TEL expression levels, we show here that TEL regulates 
Stat3’s anti-proliferative effects. Recent studies suggest that TEL might also control 
Stat3’s oncogenic activity. Indeed, it has been shown that TEL-43 inhibits transformation 
of NIH-3T3 fibroblasts by Src (51), which is known to depend upon Stat3 for its 
oncogenic activity (7,8). Our data suggest that TEL might inhibit Src-induced 
transformation through its ability to repress Stat3 activity. 
 The fact that inhibition of TEL nuclear function is required for Src to induce 
cellular transformation (51) suggests that the balance between Stat3-activating signals 
and Stat3-repressing signals determines the biological outcome. Excessive signaling to 
Stat3, which is known to occur in many tumors, has been associated with abnormal 
activity of intracellular kinases, growth factor and cytokine receptors (9,52-54). Recent 
studies demonstrate that persistent Stat3 signaling can also result from the silencing of 
negative regulators, such as SOCS1 or PIAS3 (55,56). The absence of TEL might have a 
similar role in some tumors and especially leukemias.  
 The TEL gene is often disrupted by chromosomal translocation in leukemia, most 
commonly with AML-1 (t (12;21)), resulting in production of a TEL-AML fusion 
proteins. This is often associated with loss a of heterozygosity (57,58). Fusions of TEL 
with the ABL and JAK2 tyrosine kinases, leading to constitutively active kinases, have 
also been reported (58-61).  Interestingly, TEL-JAK2 and TEL-ABL fusion proteins 
induce constitutive activation of Stat3, which was shown to cause hematopoietic 
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 precursor cell transformation (9). Our results suggest that chromosomal translocations 
involving TEL could promote transformation, not only through JAK- or ABL-mediated 
activation of Stat3, but also through attenuation of TEL-mediated negative regulation of 
Stat3 due to the loss of one TEL allele, especially if the non-rearranged TEL allele is also 
lost or mutated (58,59,61). Our data showing that TEL is a novel type of negative 
regulator of Stat3 activity call for further analysis of the impact of TEL on Stat3 biology.     
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 FOOTNOTES 
 
1 The abbreviations used are: Stat3, signal transducer and activator of transcription 3; IL-
6, interleukin-6; OSM, oncostatin M; JAK, Janus kinase; MAPK, mitogen-activated 
protein kinase; PI3K, phosphatidylinositol-3 kinase; SOCS, suppressor of cytokine 
signaling; C/EBPδ, CCAAT/enhancer-binding protein delta; 4HT, 4-hydroxytamoxifen; 
HDAC, histone deacetylase; TSA, Trichostatin A; FACS, fluorescence-activated cell 
sorter 
2 N. Schick and A. Badache, unpublished observations. 
3 N. Schick and A. Badache, unpublished observations. 
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 FIGURE LEGENDS 
Fig. 1. Stat3 activation inhibits A375 melanoma cell proliferation (A) Nuclear extracts 
from ASER cells stimulated with 1 µM 4HT for the indicated times were incubated with 
an immobilized Stat3 consensus oligonucleotide and the amount of bound Stat3ER was 
analyzed by western blotting. (B) ASER cells transfected with an APRE-luciferase 
reporter and the Renilla plasmid were treated with OSM, 4HT or the combination of 
OSM and 4HT for 24h. Luciferase activity was determined and normalized to the Renilla 
internal control. (C) ASER cells were stimulated with 100 ng/ml OSM, 1 µM 4HT or the 
combination of OSM and 4HT and cell number was determined at the times indicated. 
The experiments were performed a minimum of three times and a typical result is shown. 
Bars represent averages of three determinations +/- SD. 
 
Fig. 2. OSM and 4HT synergize to induce Stat3 activity. (A) Schematic representation of 
chimeric receptors containing the extracellular and transmembrane region of the mouse 
erythropoietin (EPO) receptor fused to various portions of the gp130 cytoplasmic 
domain. EG: chimera with the full length gp130 cytoplasmic tail; ∆B: truncated gp130 
construct containing only the membrane proximal box1/box2 region; Y759 and Y814: 
∆B with a fusion of ‘tyrosine modules’ mediating SHP2 or Stat3 respectively. (B) A375 
cells were co-transfected with constructs coding for the indicated chimeric receptor and 
the Stat3-ER together with an APRE-luciferase reporter plasmid and a Renilla plasmid, 
before stimulation with EPO (3.5 U/ml), 1 µM 4HT  or EPO/4HT for 24 h. Luciferase 
activity was normalized to the Renilla internal control. (C) ASER cells were treated with 
4HT or the combination of 4HT and OSM for the indicated times. Binding of Stat3ER 
 111
 and Stat3 to an immobilized Stat3 specific consensus DNA probe was analyzed as 
described in Fig. 1. The blot was stripped and re-probed for phosphorylation of Stat3 
Tyr705 (PY-Stat3). 
 
Fig. 3. Stat3-mediated effects on cell cycle distribution of ASER cells. Cultures were 
treated with 1 µM 4HT (A) or OSM/4HT (C) for 24 h. Cells were harvested and nuclei 
were stained with propidium iodide, before flow cytometry was performed. 
Representative histograms are shown. Changes in the percentage of cells in each phase of 
the cell cycle is indicated. (B) Cells were synchronized in G1 phase then released into 
control or 4HT-containing medium and cell cycle distribution was analyzed at the 
indicated times. (D) Western blotting analysis of regulators of the G1-S transition in 
lysates from ASER cells treated with 4HT, OSM or the combination of 4HT and OSM 
for 24 h.   
  
Fig. 4. Stat3 target genes. Genes whose expression was changed after 24 h 4HT-treatment 
of ASER cells were identified and hierachichally clustered, based on their expression 
levels after 4 h 4HT, 24 h OSM, 24 h 4HT and 24 h OSM/4HT treatments. Data are 
presented in a matrix format: each row represents a single gene, and each column an 
experimental sample. Red represents expression above and blue represents expression 
below the median value. Experiments are indicated at the top and genes are listed on the 
right. 
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 Fig. 5. C/EBPδ mediates anti-proliferative effects of Stat3. ASER cells were transfected 
with control siRNA (LacZ) or C/EBPδ siRNA for 48 h prior to 4HT treatment. (A) The 
levels of C/EBPδ mRNA after stimulation with 4HT for 24 h were analyzed by 
quantitative radioactive RT-PCR. The radioactive products were separated by 
polyacrylamide gel electrophoresis and imaged using a PhosphorImager. (B) Cell 
numbers were determined after stimulation with 4HT for 72 h. Percentage of inhibition 
induced by 4HT relative to unstimulated cells is shown. 
 
Fig. 6. TEL protein level is increased following Stat3 activation in human cancer cells. 
(A) ASER cells were stimulated with 4HT for the indicated times, nuclear extracts were 
prepared and the abundance of TEL protein was determined by immunoblot analysis. (B) 
Various human cancer cell lines were stimulated for 24 h with OSM or IL-6, nuclear 
extracts were prepared and the protein level of TEL and active Stat3 (PY-Stat3) was 
determined by western blotting. 
 
Fig. 7. TEL is a negative regulator of Stat3 activity. Cells were transfected with LacZ 
siRNA or TEL siRNA for 48 h prior to further treatments. (A) TEL protein levels were 
evaluated in nuclear lysates from cells treated with 4HT for 24 h. (B) ASER cell number 
was determined after 72 h 4HT or OSM treatment and expressed as percentage of 
inhibition relative to unstimulated cells. (C) ASER cells were transfected with an APRE-
luciferase reporter plasmid and a Renilla plasmid and Stat3 activity was assessed after 
addition of 4HT or OSM for 24 h. Luciferase activity was normalized to the Renilla 
internal control. 
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Fig. 8. TEL-induced repression of Stat3 transcriptional activity does not require the TEL 
DNA binding domain but depends on the TEL pointed domain. (A) ASER cells were 
transfected with the TEL construct along with an APRE-luciferase reporter plasmid and a 
Renilla plasmid 24 h prior to stimulated with 4HT alone or 4HT and TSA (250nM) for 24 
h. Luciferase activity was normalized to the Renilla internal control. (B) Schematic 
diagram of TEL mutants. DBDM: DNA-binding domain mutant, P: Pointed domain. (C 
and D) ASER cells and HEK-293T cells were transfected with the different TEL mutants, 
an APRE-luciferase reporter plasmid and a Renilla plasmid. Cells were treated with 4HT 
or OSM for 24 h, before determination of  luciferase activity. 
 
Fig. 9. TEL interacts with Stat3. Nuclear extracts were prepared from control or OSM-
treated ASER cells. Left panel: extracts were subjected to immunoprecipitation (IP) with 
anti-Stat3 antibody and analyzed by western blotting using anti-TEL and anti-Stat3 
antibodies. Middle panel: TEL was pulled down using an immoblized ETS consensus 
site-containing oligonucleotide before western blotting analysis with anti-TEL and anti-
Stat3 antibodies. Right panel: levels of Stat3 and TEL in total nuclear lysates were 
determined by western blotting. 
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 IV. Appendix 
Figure 1: Stat3ER protein levels increase after 24 h treatment of ASER cells with 4HT  
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 Figure 2: 1 µM 4HT is the optimal concentration to stimulate APRE reporter activity in 
ASER cells 
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 Figure 3: A375 cell proliferation is not reduced after stimulation with 1 µM 4HT  
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 Figure 4: Stimulation of ASER cells with IL-6 (10 ng/ml) and 4HT (1 µM) shows the 
same cooperative effect that was observed with OSM and 4HT.  
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 Figure 5: Stimulation of A375 cells with IL-6 and OSM leads to a dose dependent 
increase in the activity of the JAK/STAT, MAPK and PI3K signaling pathways. 
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 Figure 6: Stimulation of ASER cells with 100 ng/ml OSM does not affect the cell cycle 
profile after 48h and 72h of treatment. 
 
 Cells were harvested after times indicated and nuclei were stained with propidium 
iodide, before flow cytometry was performed. Changes in the percentage of cells in 
each phase of the cell cycle are indicated. 
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 Figure 7: Simultaneous treatment of ASER cells with 100 ng/ml OSM and 1 µM 4HT 
leads to apoptosis as demonstrated by a sub-G1 peak. 
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 Figure 8: Simultaneous treatment of ASER cells with 100 ng/ml OSM and 1 µM 4HT 
for 24 h leads to increased association of p27Kip1.with cdk2. 
 
  Nuclear extracts were prepared from ASER cells treated with the stimuli 
indicated. Extracts were subjected to immunoprecipitation (IP) with anti-cdk2 
antibody and analyzed by western blotting using anti-p27 antibody. 
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 Figure 9: Two independent ASER clones show a similar response to 4HT treatment 
with respect to DNA binding, reporter gene assays and inhibition of cell proliferation. 
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  cell proliferation assay of two ASER clones stimulated with 4HT or OSM for 
72 h. 
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 Figure 10: Stat3 reporter gene activity was strongly increased in ASER cells between 2 
& 4 h of 4HT treatment. 
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 Figure 11: Microarray data showing that expression of several known Stat3 targets was 
increased after 4 h of 4HT treatment of ASER cells.  
 
Gene Fold increase (relative 
to control) 
SOCS3 9.9 
C/EBP δ 3.92 
JunB 2.40 
Serpin A3 2.27 
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 Figure 12: Stimulation of ASER cells with 4HT and OSM triggeres the activation or 
repression of many more genes than stimulation of ASER cell with 4HT alone. 
 
 Venn diagram of genes whose expression was increased more than 1.5 fold or 
decreased more than 1.3 fold after treatment of ASER cells with 4HT and OSM or 
4HT alone. 
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 Figure 13: Overexpression of TEL did not affect Stat3 expression levels or nuclear 
translocation and DNA binding in response to treatment with OSM. 
 
 Stat3 and TEL western blot of whole cell extracts of ASER cells transfected with 
control or TEL plasmids. 
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 Stat3 DNA binding assay of nuclear extracts of ASER cells transfected with TEL, 
followed by stimulation with OSM for 30 min. 
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 Figure 14: Microarray data showing that two known Stat3 target genes, 
angiotensinogen and PIM 1, were only upregulated after 24 h stimulation of ASER cells 
with 4HT and OSM together. 
 
Gene Fold increase  
(relative to control) 
angiotensinogen 11.59 
Pim 1 6.96 
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 Figure 15: The TEL DBD is not essential for repression of Stat3 transcriptional activity. 
 
  Schematic diagram of TEL ∆DBDM mutant. 
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  Stat3 reporter assay of ASER cell transfected with control, TEL or TEL ∆DBDM 
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 VII. Discussion 
Cancer is a disease of deregulated cell proliferation and suppressed apoptosis, resulting 
from changes in gene expression that allow the cell to overcome normal growth 
inhibitory signals. In contrast to untransformed cells, which double only a limited time in 
culture and in vivo, most malignant tumor cells have the potential to grow indefinitely. It 
became clear in recent years that cancer arises through stepwise mutations, be it through 
exposure to some environmental factor (e.g. tobacco smoke) or because of a genetic 
predisposition, or both, that usually occur over a long timeframe. These mutations can be 
either as subtle as point mutations, or as obvious as changes in chromosome complement 
and they can cause either transformation of normal genes into oncogenes (gain-of-
function) or loss of a tumor suppressor gene. Taken together, cancer development occurs 
via a stepwise acquisition of mutations, which lead to six essential features of a cancerous 
cell including; self-sufficiency in growth signals, insensitivity to growth -inhibitory 
signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis and 
tissue invasion and metastasis (Hanahan and Weinberg, 2000).  
Traditionally, cancer drug discovery was pointed towards targeting DNA synthesis and 
cell division, resulting in drugs such as antimetabolites and alkylating agents that are 
efficient but often show severe side effects, since they lack selectivity for tumor cells 
compared to normal cells. From the 1980s onwards, a more targeted drug discovery 
approach has been developed, which focuses on specific key proteins in cell proliferation, 
such as tyrosine kinases. An advantage of the new model for anticancer drug discovery is 
likely to be targeted specificity leading to limited side effects. There are different 
possibilities to design a cancer drug; two successful options are the use of antibodies that 
block cell-surface receptors or small molecular drugs. Antibodies have the disadvantage 
that they are limited to proteins that span the plasma membrane since they cannot gain 
access to the interior of the cell. This weakness is balanced by the fact that they are more 
specific compared to small molecular drugs due to the unlikeliness that they inhibit other 
proteins. Herceptin, a monoclonal antibody against the Her2/neu receptor tyrosine kinase, 
is one of the best-studied antibodies and prolongs the survival of women with Her2/neu 
positive metastatic breast cancer in combination with chemotherapy. One example for a 
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 small molecular kinase inhibitor is Gleevec, a drug that inhibits BCR–ABL, c-KIT and 
PDGFR and has shown remarkable success for the treatment of CML (chronic myeloid 
leukemia), a pluripotent stem cell disorder characterized by the Philadelphia chromosome 
translocation, generating Bcr-Abl (Sawyers, 2002). In recent years it has become 
apparent that transcription factors are good targets for cancer drug discovery. Two 
reasons speak for this; first, it is known that a limited set of transcription factors is 
constitutively active in most human cancers; second, there are many more human 
oncogenes in signaling pathways than there are oncogenic transcription factors, so 
blocking one transcription factor might inhibit multiple upstream oncoproteins as well. 
Three groups of transcription factors seem to play a role in cancer: The nuclear receptors, 
for example oestrogen receptors in breast cancer, androgen receptors in prostate cancer 
and retinoic-acid receptors (RAR) in acute promyelocytic leukemia (APL); the second 
group of transcription factors are resident nuclear proteins that are activated by serine 
kinase cascades, such as c-jun; the third group are latent cytoplasmic factors, which are 
normally activated by receptor ligand interaction at the cell surface, for instance NF-κB, 
β-catenin, notch intracellular domain and STATs. However, the inhibition of specific 
transcription factors or inhibition of their interactions with coactivators or accessory 
proteins is not an easy task and so far the only drugs available that target transcription 
factors are tamoxifen, bicalutamide or retinoids, which target oestrogen-, androgen- and 
retinoic-acid receptors (Altucci and Gronemeyer, 2001; Darnell, 2002).  
As mentioned above STATs might be important for cancer progression since two 
members of the family, Stat3 and Stat5, are constitutively activated in a wide variety of 
human malignancies. Stat5 is mainly associated with various types of lymphomas and 
leukemias and it clearly implicated in cancer progression, whereas there are conflicting 
observations reported for Stat3. It is thought that Stat3 plays a critical role in cancer, 
given that constitutively active Stat3 is present in various cancers such as squamous cell 
carcinoma of the head and neck (SCCHN), breast, melanoma and prostate cancer cells 
(Bowman et al., 2000; Grandis et al., 2000; Leong et al., 2003; Mora et al., 2002) as well 
as in cells transformed by oncogenes, such as v-src and v-abl (Cao et al., 1996; Danial et 
al., 1995; Yu et al., 1995). The critical role of Stat3 was proven by experiments 
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 performed with dominant negative Stat3, since this blocked the transformation induced 
by v-src (Bromberg et al., 1998; Turkson et al., 1998) and induced growth arrest and 
apoptosis in a wide variety of cancer cells (Darnell, 2002). Furthermore, transfection of 
cultured cells with Stat3-C, a constitutively active Stat3 mutant, can transform cells 
(Bromberg et al., 1999). These are all examples, in which constitutively Stat3 activity 
was induced via oncogenes or aberrant signaling of cytokines or growth factors 
associated JAKs. However, there is also a vast amount of data showing that controlled 
Stat3 activation via cytokine stimulation does not lead to transformation, and even 
inhibits cell proliferation and/or induces apoptosis of normal and cancerous cells 
(Kortylewski et al., 1999; Minami et al., 1996). Our findings indicate that Stat3 activation 
alone is sufficient to inhibit proliferation of cells that are inhibited in cell proliferation by 
IL-6 type cytokine stimulation. Furthermore, strong and prolonged activation of Stat3 
leads to growth arrest and apoptosis. Taken together, the results in the literature and ours 
suggest that it might be desirable to inhibit Stat3 signaling in cancer cells showing 
constitutively active Stat3 signaling, and to activate Stat3 signaling in tumor cells that are 
inhibited in cell proliferation upon cytokine signaling, to induce in both cases growth 
arrest and apoptosis. Considering all this, it might be important to check the Stat3 status 
and the status of known Stat3 target genes to conclude if Stat3 activity leads to either a 
growth advantage or to a disadvantage. Our data will be very valuable to assess this issue, 
since we identified Stat3 target genes in cancer cells that are growth inhibited after Stat3 
activation, an approach that was not undertaken so far. It is therefore essential to identify 
the Stat3- and the Stat3 target genes status in the cancerous tissue in order to achieve 
effective patient tailored cancer therapy. 
Given the fact that the biological readout of activated Stat3 in the cases mentioned above 
can be growth stimulation or inhibition, suggests that the genes, which are 
transcriptionaly activated by Stat3 might be different in both circumstances. In fact, in 
our experiments we were not able to detect the majority of the published Stat3 target 
genes, which is not surprising since these genes have been mainly identified in cells that 
respond to Stat3 activation with accelerated cell proliferation. Among the known target 
genes, our analyses has revealed only genes that do not seem to have a function in 
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 stimulating cell proliferation, such as SOCS3, serpin A3, and VEGF. Interestingly only 
C/EBPδ, a protein that we have identified as being a mediator of the Stat3 induced 
inhibition of cell proliferation, had previously been identified as a Stat3 target. Other 
interesting targets, we identified, have not been found in cells that are growth promoted 
by Stat3 (discussed below). The dissimilarity in identified Stat3 target genes between our 
results and published results could have cell specific origins including differences in 
transcription factors, coactivators, corepressors, chromatin remodelers, histone 
acetylases, deacetylases, kinases and methylases. These are all required for the regulation 
of gene expression and play important roles in generating the promoter and tissue specific 
responses of a transcription factor (Orphanides and Reinberg, 2002). The interesting 
Stat3 targets identified in our studies after short treatment (4h) with 4HT are discussed 
below.  
Several reports have demonstrated that C/EBPδ is a downstream target of Stat3. The 
C/EBPδ promoter contains a Stat3 binding site and C/EBPδ is up-regulated after OSM 
treatment of mammary cells (Hutt et al., 2000; O'Rourke et al., 1997). Our results 
showing the importance of C/EBPδ as a Stat3 target and mediator of Stat3 induced 
growth inhibition of melanoma cells are in agreement with these studies and with another 
study showing that C/EBPδ  is important for G0 growth arrest of mouse mammary 
epithelial cells (Hutt and DeWille, 2002). It is important to note, however, that the 
C/EBPδ mediated suppression of melanoma cell proliferation, described in this thesis, 
does not lead to an observed reduction of cells in S phase and increase of cells in G0-G1 
phase of the cell cycle described by Hutt et al. (Hutt and DeWille, 2002). This might be 
due to different cell types used in the experiments. Interestingly, while siRNA mediated 
knockout of C/EBPδ had no effect on the G1 block induced by combined stimulation 
with 4HT and OSM (data not shown) it partially rescued 4HT induced inhibition in cell 
proliferation. We propose, that C/EBPδ is a mediator of Stat3 induced inhibition of 
melanoma cells proliferation, but not of Stat3 induced cell cycle arrest and apoptosis.  
Osteopontin (OPN), a ligand for CD44 and most integrin receptors (Furger et al., 2001) is 
another Stat3 target gene we identified. Analysis of OPN-null mice revealed its important 
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 function in would healing, which is in accordance with the data of a tissue-specific 
knockout of Stat3 in keratinocytes in which wound healing processes are severely 
compromised (Liaw et al., 1998; Sano et al., 1999). It could, therefore, be speculated that 
the observed phenotype in Stat3-null mice in keratinocytes might be due to insufficient 
up-regulation of OPN; further investigations will be necessary to prove this. Osteopontin 
has also been shown to be a marker for cancer progression, since elevated levels of 
osteopontin have been detected in various cancers, especially head and neck cancer, 
squamous cell carcinomas, hepatocellular and breast carcinomas (Le et al., 2003; Pan et 
al., 2003; Wang-Rodriguez et al., 2003). Interestingly, Stat3 is frequently activated in 
these types of tumors and contributes to cellular transformation (Garcia et al., 2001; 
Grandis et al., 2000; Yoshikawa et al., 2001). It will be of interest to characterize whether 
elevated levels of osteopontin might be a consequence of Stat3 activity. 
 
Death-associated protein kinase 1 (DAPK1), a pro-apoptotic, Ca2+/calmodulin (CaM)-
regulated serine/threonine kinase, which functions as a positive mediator of apoptosis 
(Shohat et al., 2002), was rapidly increased upon Stat3 activation in our studies. While 
this up-regulation was not accompanied by increased apoptosis, synergisitic enhancement 
of Stat3 activity by 4HT and OSM, led to strongly increased expression of DAPK1 and 
cell death. The possible contribution of DAPK1 to Stat3-mediated apoptosis remains to 
be determined. We did not observe any signs of apoptosis in melanoma cells after limited 
DAPK1 up-regulation by 4HT stimulation. This might be due the insufficient 
upregulation or inactivation by posttranslational modifications e.g. phosphorylation in the 
CaM regulatory domain, which inactivates the kinase. Interestingly, DAPK1 expression 
is frequently lost in various tumor cell lines, which gives a selective advantage to cancer 
cells and might play a causative role in tumor progression (Raveh and Kimchi, 2001). 
Inactivation of tumor-suppressor genes such as DAPK1 occurs in many cases through 
mutation or loss of large portion of their genetic sequence or through hypermethylation of 
CpG islands located in the promoter region. Indeed, DAPK1 has been found to be 
silenced by methylation in ~ 15 % of human tumors, for example in gastric, lung, 
bladder, breast, and head and neck cancer, (Chan et al., 2002; Esteller et al., 1999; Lee et 
al., 2002; Rosas et al., 2001; Sanchez-Cespedes et al., 2000).  
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 It might further be of great interest to analyze tumors, which are positive for 
phosphorylated Stat3, for mutations in some of the genes mentioned above. Loss of 
proteins that are important for inhibition of cell proliferation or for induction of apoptosis 
might be a reason that in some cases, tumor cells demonstrate a growth advantage with 
constitutively activated Stat3. In addition, these genes might be important markers for 
tumors with activated Stat3, where Stat3 activation is necessary for inhibition of cell 
proliferation, which should not be targeted by Stat3 blocking reagents. 
 
The TEL transcription factor a novel negative regulator of Stat3 
 
In this thesis I describe a novel Stat3 target, TEL (ETV6), that is induced after Stat3 
activation in a panel of cell lines. We also show that TEL represses Stat3 transcriptional 
activity as well as Stat3’s biological effects. Therefore, TEL is involved in a Stat3 
negative feedback loop. The known negative regulators of Stat3 signaling inhibit Stat3 
activity by various means. Nuclear and cytoplasmic phosphatases dephosphorylate Stat3 
(ten Hoeve et al., 2002; Yamamoto et al., 2002); SOCS3 inhibits JAK activity, therefore 
abolishing Stat3 tyrosine phosphorylation and activation (Croker et al., 2003; Krebs and 
Hilton, 2000); GRIM-19 inhibits Stat3 activity by blocking its nuclear translocation and 
thus preventing Stat3 DNA-binding (Lufei et al., 2003; Zhang et al., 2003); and PIAS3, a 
nuclear inhibitor, blocks the DNA-binding activity of Stat3 via interaction with Stat3 
(Figure 19)(Chung et al., 1997). In contrast, TEL does not inhibit Stat3 nuclear 
translocation and DNA binding after OSM stimulation. Based on these observations it 
appears that the mechanism of repression of Stat3 by TEL is different from the known 
inhibitors of Stat3. TEL does not inhibit Stat3 DNA binding but rather its transcriptional 
activity. We also addressed the mechanism whereby TEL represses Stat3 activity in our 
work 
 
Transcription in eukaryotic cells is influenced by the way in which DNA is packaged into 
chromatin, which is a dynamic macromolecular complex that consists of DNA, histones, 
and non-histone proteins. The fundamental subunit of chromatin, the nucleosome, is 
composed of an octamer of four core histones –an H3-H4 tetramer and two H2A-H2B 
dimers surrounded by 146 bp of DNA. This compact, inaccessible DNA is 
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 transcriptionally repressed, whereas transcriptionally active genes are found in areas of 
open chromatin, which results from modifications of the nucleosomes. The charged 
amino-terminal “tails” of histones extend out of the nucleosomes and are targeted for 
various post-translational modifications, including acetylation, phosphorylation and 
methylation. Acetylation, the best understood modification, occurs at the ε amino groups 
of conserved lysine residues located at the N-terminus of all core histones. In general, 
increased levels of histone acteylation (hyperacetylation) are associated with increased 
transcriptional activity, whereas decreased acetylation (hypoacetylation) is associated 
with repression of gene expression. The balance between the opposing activities of 
histone acetyltransferases (HATs) and histone deactylases (HDACs) controls the steady-
state level of histone acetylation. Three classes of HDACs have been identified that 
include 17 proven or putative HDACs. Class I human HDACs include HDAC1, HDAC2, 
HDAC3 and HDAC8 and seem to be nuclear localized. They bind to numerous 
transcription factors, either directly or indirectly, through other proteins such as the 
nuclear-receptor corepressor (N-CoR), the silencing mediator for retinoic acid and 
thyroid hormone receptor (SMRT) protein and through complexes that include mSin3A 
and NuRD (nucleosomes remodeling and deacetylating). Class II human HDACs include 
HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10, and they shuttle between 
the cytoplasm and the nucleus. Class II HDACs can also bind to SMRT and N-CoR, 
however, they do not form complexes with mSin3A and NuRD (de Ruijter et al., 2003). 
Previous studies demonstrated that the recruitment of a repressor complex comprising 
mSin3A, N-CoR and HDACs is necessary for TEL-induced repression (Chakrabarti and 
Nucifora, 1999; Fenrick et al., 1999; Guidez et al., 2000; Wang and Hiebert, 2001). In 
particular, HDAC3 was shown to associate with TEL’s central region (Wang and Hiebert, 
2001). Even though we could show with Trichostatin A (TSA), a general HDAC 
inhibitor, that TEL-mediated repression of Stat3 is also dependent on HDAC activity, the 
central domain is not essential for the effect, suggesting an alternative mechanism for 
repression of Stat3. Furthermore, recent studies suggest that the tat-interactive protein, 
60kDa (Tip60), a histone acetyltransferase, could be an element of the TEL co-repressor 
complex. Indeed, it was shown that Tip60 interacts with and acts as a transcriptional co-
repressor of TEL (Nordentoft and Jorgensen, 2003). Moreover Tip60, together with 
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 HDAC7, was found to interact with Stat3 and to repress Stat3 activity (Xiao et al., 2003) 
suggesting that Tip60 might be part of the TEL co-repressor complex for Stat3 activity. 
However, that study describes that the ETS domain is the interaction domain for TEL and 
Tip60 and we have evidence that the ETS domain is not essential for repression of Stat3 
activity. In fact, we have been able to demonstrate that TEL interacts with Stat3. This 
suggests that TEL might be recruited to Stat3 via protein-protein interaction and not by 
direct binding to the DNA. It would be of great interest to identify the components of the 
protein complex that are involved in repression of Stat3 activity.  
 
Several recent reports highlight the importance of the known negative regulators of Stat3 
in cancer. SOCS 1 expression was found to be silenced by aberrant methylation of CpG 
islands located in the SOCS1 promoter region in 65% of 26 human primary 
hepatocellular carcinoma (HCC) tumor samples. In cells where SOCS-1 was silenced by 
methylation and JAK2 was constitutively activated, re-introduction of the SOCS-1 
protein suppressed growth and induced apoptosis (Yoshikawa et al., 2001). 
Hypermethylation of the SOCS1 promoter was also observed in 63 % of human multiple 
myelomas, 60 % of acute myeloid leukemia, and in 67 % of chronic myeloid leukemia 
(Chen et al., 2003; Galm et al., 2003; Liu et al., 2003). Moreover a new study showed 
that SOCS3 is frequently silenced by hypermethylation in breast- and lung cancer cell 
lines and in primary lung cancer tissue. Silencing was associated with higher levels of 
phosphorylated Stat3; restoration of SOCS3 lead to suppression of cell growth and 
apoptosis (He et al., 2003). Constitutively active Stat3 has also been shown in anaplastic 
large cell lymphoma where PIAS3 expression was silenced (Zhang et al., 2002). 
Considering these results, the loss of a negative regulator of Stat3 appears to bring 
growth advantages to cancer cells. There is accumulating evidence that TEL might be lost 
in cancer as shown in acute lymphoblastic leukemia of childhood, and in ovarian- and 
prostate cancer (Hatta et al., 1997; Kibel et al., 2002; Stegmaier et al., 1995). Since we 
found that TEL is a Stat3 inhibitor, loss of TEL could, therefore, contribute to Stat3’s 
oncogenic abilities. Further analysis will be necessary to screen for TEL deletions and/or 
mutations in cancers that show constitutive active Stat3 signaling and to evaluate whether 
loss of TEL contributes to cancer development. 
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Figure 19: Model of the negative regulation of Stat3 signaling.  
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